

# British HIV Association guidelines for the management of TB/HIV co-infection in adults 2017

## *Writing group members*

Anton Pozniak (Chair), *Chelsea and Westminster Hospital NHS Foundation Trust*

Margherita Bracchi, *Chelsea and Westminster Hospital NHS Foundation Trust*

Funmi Awosusi, *Barts Health NHS Trust, HIVPA*

Alison Barbour, *Croydon Health Services NHS Trust*

Steve Bradley, *UK-CAB*

Katherine Coyne, *Homerton University Hospital*

Esther Dixon-Williams, *UK-CAB*

Andrew Freedman, *Cardiff University School of Medicine*

Pauline Jelliman, *Liverpool Community Health NHS Trust, NHVNA*

Saye Khoo, *University of Liverpool*

Clifford Leen, *NHS Lothian*

Marc Lipman, *Royal Free London NHS Foundation Trust*

Sebastian Lucas, *Guy's & St Thomas' Hospital NHS Foundation Trust*

Rob Miller, *Mortimer Market Centre*

Frank Post, *King's College London*

Kay Seden, *University of Liverpool*

Clare van Halsema, *Liverpool School of Tropical Medicine*

*These guidelines are dedicated to the memory of Professor Stephen Lawn, a scientist and clinician whose pioneering work helped transform the management of TB in people living with HIV.*

Consultation draft

## Contents

<b>1 Scope and purpose</b>	<b>8</b>
1.1 Guideline development process	8
1.2 Involvement of PLWH	8
1.3 GRADE	8
1.4 Good practice points	9
1.5 Dissemination and implementation	9
1.6 Guideline updates and date of next review	9
1.7 References	10
<b>2 Recommendations</b>	<b>11</b>
Diagnosis of active pulmonary TB	11
Diagnosis of active extra-pulmonary TB	11
Diagnosis of multidrug-resistant TB infection	11
Diagnosis of latent TB infection	11
Treatment of latent TB infection	11
Treatment of active drug-sensitive TB	12
Management of treatment failure and relapse	12
Management of drug-resistant TB	12
Directly observed therapy (DOT)	12
Choice of antiretroviral treatment in individuals not on ART	12
When to start ART	12
What ART to start	13
Choice of antiretroviral treatment in individuals on established ART	13
Drug interactions and toxicities	13
IRIS (IRIS diagnosis/management)	13
Pregnancy and breastfeeding	13
Prevention and control of transmission	13
Notification/tracing of contacts	13
<b>3 Introduction</b>	<b>14</b>
3.1 References	15
<b>4 Aims of TB treatment</b>	<b>16</b>
4.1 References	16
<b>5 Diagnosis of active TB/HIV (diagnostic tests)</b>	<b>17</b>
5.1 Pulmonary TB diagnosis in HIV	17
5.1.1 Rationale	17
5.2 Extra-pulmonary TB diagnosis (EPTB)	17

5.2.1 TB of the CNS .....	17
5.2.2 Rationale .....	18
5.3 TB pleuritis.....	18
5.3.1 Rationale .....	18
5.4 Lymph node TB and disseminated TB.....	19
5.4.1 Rationale .....	19
5.5 Cytopathology (lymph nodes, lung aspirate, focal lesions) .....	19
5.6 Histopathology.....	19
5.7 Diagnosis of multidrug-resistant TB .....	20
5.7.1 Rationale .....	20
5.8 References .....	20
<b>6 Diagnosis and treatment of latent TB in HIV-infected adults .....</b>	<b>22</b>
6.1 Diagnosis of latent TB.....	22
6.1.1 Rationale .....	22
6.2 Treatment of latent TB infection .....	24
6.2.1 Rationale .....	24
6.3 Drug-resistant TB after treatment of LTBI.....	25
6.4 Secondary prophylaxis after treatment for active TB and longer-term isoniazid preventive therapy.....	25
6.5 Treatment of LTBI in individuals exposed to drug-resistant TB .....	25
6.6 References .....	26
<b>7 Treatment of active drug-sensitive TB .....</b>	<b>28</b>
7.1 Rationale .....	28
7.2 Interruptions of therapy .....	29
7.3 Investigations and monitoring.....	30
7.4 References .....	30
<b>8 Management of relapse, treatment failure and drug-resistant TB including directly observed therapy (DOT)</b>	<b>32</b>
8.1 Management of treatment failure and relapse.....	32
8.2 Rationale .....	32
8.2.1 Definitions.....	32
8.3 Management of drug-resistant TB .....	33
8.3.1 Rationale .....	33
8.3.2 Treatment regimens (adapted from [8]).....	33
8.3.2 Duration of MDR/XDR treatment.....	34
8.3.4 Newer Drugs .....	35
8.4 Directly observed therapy (DOT) .....	36
8.4.1 Rationale .....	36
8.5 References .....	36

<b>9 When to start ART .....</b>	<b>38</b>
9.1 Choice of antiretroviral treatment in individuals not on ART: when and what to start .....	38
9.1.1 Rationale .....	38
9.1.2 Rationale .....	38
9.2 What ART to start in TB/HIV co-infection.....	38
9.2.1 Rationale .....	38
9.3 Choice of antiretroviral treatment in individuals on established ART .....	39
9.3.1 Rationale .....	39
9.4 References .....	39
<b>10 Drug–drug interactions .....</b>	<b>42</b>
10.1 ART/TB drug interactions and TDM use and interpretation (including MDR and XDR).....	42
10.2 DDIs between TB and HIV drugs.....	42
10.2.1 Other DDIs.....	43
10.2.2 Managing DDIs .....	44
10.2.3 Therapeutic drug monitoring (TDM) .....	44
10.3 References .....	44
<b>11 Drug absorption, toxicity and management .....</b>	<b>52</b>
11.1 Malabsorption of drugs .....	52
11.2 Overlapping toxicity profiles of antiretrovirals and TB therapy.....	52
11.3 Drug induced liver injury (DILI) .....	52
11.3.1 Management of suspected DILI .....	52
11.4 Pre-existing liver disease .....	53
11.5 Gastrointestinal side effects .....	53
11.6 Peripheral neuropathy.....	54
11.7 Rash .....	54
11.8 Reintroduction of TB drugs after DILI or rash .....	54
11.9 References .....	55
<b>12 Immune reconstitution inflammatory syndrome .....</b>	<b>60</b>
12.1 Rationale .....	60
12.2 Definition.....	60
12.3 Epidemiology of IRIS (see also Appendix 7) .....	60
12.4 Clinical features of IRIS .....	61
12.5 Management of IRIS.....	61
12.5.1 Corticosteroids.....	61
12.5.2 Other treatment options.....	61
12.6 References .....	61
<b>13. Pregnancy and breastfeeding.....</b>	<b>64</b>
13.1 Rationale .....	64

13.2 References .....	65
<b>14. Prevention and control of transmission .....</b>	<b>66</b>
14.1 Hospital care of individuals with potential or known TB requires: considerations .....	66
14.2 Adequate protection of healthcare workers and other contacts.....	66
14.3 Recommended reading.....	67
<b>15. Notification/tracing of contacts .....</b>	<b>68</b>
15.1 NICE guidelines [1].....	68
15.2 Assessing the need for tracing social contacts of people with pulmonary or laryngeal TB.....	68
15.3 Offer 'inform and advise' information to all contacts of people with smear-positive TB.....	68
15.3 Notification.....	68
15.4 References .....	68
<b>16. Death and clinico-pathological audit.....</b>	<b>69</b>
Appendix 1. Summary of the modified GRADE system .....	70
References .....	70
Appendix 2. Systematic literature search .....	72
QUESTIONS and PICO criteria .....	72
Search 1: Diagnosing active TB in HIV-infected adults.....	72
Search 2: Latent TB in HIV-infected adults.....	73
Search 3: Treatment of active TB in HIV .....	73
Search 4: Drug toxicity .....	74
Search 5: Starting ART.....	74
Search 6: Diagnosing and managing immune reconstitution inflammatory syndrome (IRIS) .....	74
Search 7: Treatment failure and relapse.....	75
Search 8: Pregnant and breastfeeding women with TB/HIV .....	75
Search 9: Prevention and control of transmission .....	76
Appendix 3. Diagnosis of active TB/HIV (diagnostic tests) .....	77
Use of Rapid PCR testing.....	77
References .....	79
Appendix 4. Chemopreventive therapy .....	81
Excluding active TB.....	81
Interferon-gamma release assays (IGRAs) .....	81
References .....	81
Appendix 5. Treatment of drug-sensitive TB: drug regimens .....	83
References .....	83
Appendix 6. Drug–drug interactions of MDR TB drugs and ART .....	85
Amikacin/kanamycin/streptomycin.....	85
Capreomycin .....	85

Levofloxacin .....	85
Moxifloxacin.....	85
Para-aminosalicylic acid .....	85
Clofazimine.....	85
Bedaquiline .....	85
Delamanid .....	86
References .....	86
<i>Appendix 7. IRIS</i> .....	87
Definition [1] .....	87
Epidemiology of IRIS .....	87
References .....	88
<i>Appendix 8. When to start ART in TB/HIV infection</i> .....	89
References .....	89
<i>Appendix 9. Glossary</i> .....	90

# 1 Scope and purpose

---

These guidelines have been drawn up to help physicians manage adults with tuberculosis (TB)/HIV co-infection. Recommendations for the treatment of TB in HIV-positive adults are similar to those in HIV-negative adults.

## 1.1 Guideline development process

---

BHIVA fully revised and updated the association's guideline development manual in 2011. Further updates have been carried out subsequently [1]. Full details of the guideline development process, including conflict of interest policy, are outlined in the manual. BHIVA has adopted the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for the assessment, evaluation and grading of evidence and development of recommendations (see below and Appendix 1) [2,3].

The scope, purpose and guideline topics were agreed by the writing group. Questions concerning each guideline topic were drafted and a systematic literature search was undertaken by an information scientist.

Details of the search questions and strategy (including the definition of populations, interventions and outcomes) are outlined in Appendix 2. BHIVA guidelines for the treatment of TB/HIV-1 co-infection were last published in 2011 [4]. For the 2017 guidelines, Medline, EMBASE and the Cochrane library were searched between August 2015 and January 2016. Abstracts from selected conferences (see Appendix 2) were searched between August 2015 and January 2016. For each topic and healthcare question, evidence was identified and evaluated by writing group members with expertise in the field. Using the modified GRADE system, writing group members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. An important aspect of evaluating evidence is an understanding of the design and analysis of clinical trials, including the use of surrogate marker data. Decisions regarding the clinical importance of difference in outcomes are made by the writing group.

Before final approval by the writing group, the guidelines were published online for public consultation and an external peer review was commissioned.

## 1.2 Involvement of PLWH

---

BHIVA views the involvement of PLWH and community representatives in the guideline development process as essential. The writing group included two representatives appointed through the UK Community Advisory Board (UK-CAB) and community groups are specifically invited to participate in the public consultation process.

## 1.3 GRADE

---

The GRADE Working Group [2] has developed an approach to grading evidence that moves away from initial reliance on study design to consider the overall quality of evidence across outcomes. BHIVA has adopted the modified GRADE system for its guideline development (see Appendix 1).

The advantages of the modified GRADE system are: (i) the grading system provides an informative, transparent summary for clinicians, PLWH and policymakers by combining an explicit evaluation of the strength of the recommendation with a judgement of the quality of the evidence for each recommendation, and (ii) the two-level grading system of recommendations has the merit of simplicity and provides clear direction to PLWH, clinicians and policymakers.

The strength of recommendation is graded as 1 or 2 as follows:

- A GRADE 1 recommendation is a strong recommendation to do (or not do) something, where the benefits clearly outweigh the risks (or vice versa) for most, if not all PLWH. Most clinicians and HIV-positive individuals should and would want to follow a strong recommendation unless there is a clear rationale for an alternative approach. A strong recommendation usually starts with the standard wording 'we recommend'.

- A GRADE 2 recommendation is a weaker or conditional recommendation, where the risks and benefits are more closely balanced or are more uncertain. Most clinicians and PLWH would want to follow a weak or conditional recommendation but many would not. Alternative approaches or strategies may be reasonable depending on the HIV-positive individual's circumstances, preferences and values. A weak or conditional recommendation usually starts with the standard wording 'we suggest'.

The strength of a recommendation is determined not only by the quality of evidence for defined outcomes but also the balance between desirable and undesirable effects of a treatment or intervention, differences in values and preferences and, where appropriate, resource use. Each recommendation concerns a defined target population and is actionable.

The quality of evidence is graded from A to D and for the purpose of these guidelines is defined as the following:

- GRADE A evidence means high-quality evidence that comes from consistent results from well-performed randomised controlled trials (RCTs), or overwhelming evidence of some other sort (such as well-executed observational studies with consistent strong effects and a low likelihood of uncorrected bias). GRADE A implies confidence that the true effect lies close to the estimate of the effect.
- GRADE B evidence means moderate-quality evidence from randomised trials that suffer from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with special strengths such as observational studies with consistent effects and exclusion of most potential sources of bias.
- GRADE C evidence means low-quality evidence from controlled trials with several very serious limitations or observational studies with limited evidence on effects and exclusion of most potential sources of bias.
- GRADE D evidence is based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there is likely to be little confidence in the effect estimate.

## 1.4 Good practice points

---

In addition to graded recommendations, the BHIVA writing group has also included good practice points (GPP), which are recommendations based on the clinical judgement and experience of the working group.

GPPs emphasise an area of important clinical practice for which there is not, nor is there likely to be, any significant research evidence. They address an aspect of treatment and care that is regarded as such sound clinical practice that healthcare professionals are unlikely to question it and where the alternative recommendation is deemed unacceptable. It must be emphasised that GPPs are not an alternative to evidence-based recommendations.

## 1.5 Dissemination and implementation

---

The following measures have or will be undertaken to disseminate and aid implementation of the guidelines:

- E-publication on the BHIVA website and the journal *HIV Medicine*;
- Publication in *HIV Medicine*;
- Non-technical leaflets;
- Shortened version for BHIVA guidelines app;
- E-learning module accredited for CME;
- Educational slide set to support local and regional educational meetings;
- National BHIVA audit programme.

## 1.6 Guideline updates and date of next review

---

The guidelines will be next fully updated and revised in 2019. However, the writing group will continue to meet regularly to consider new information from high-quality studies and publish amendments and addenda to the

current recommendations before the full revision date where this is thought to be clinically important to ensure continued best clinical practice.

## 1.7 References

---

1. British HIV Association. *BHIVA Guideline Development Manual*. 28 January 2014. Available at: <http://www.bhiva.org/GuidelineDevelopmentManual.aspx> (accessed August 2015).
2. GRADE Working Group. Grading the quality of evidence and the strength of recommendations. Available at: <http://www.gradeworkinggroup.org/intro.htm> (accessed August 2015).
3. Guyatt GH, Oxman AD, Kunz R *et al*. Going from evidence to recommendations. *BMJ* 2008; **336**: 1049–1051.
4. Pozniak AL, Coyne KM, Miller RF *et al*. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. *HIV Med* 2011; **12**: 517–524.

## 2 Recommendations

---

### Diagnosis of active pulmonary TB

---

- We recommend performing microscopy for acid-fast bacilli (AFB) on respiratory samples (sputum, induced sputum or bronchoalveolar lavage [BAL]), followed by molecular testing, e.g. Xpert MTB/RIF, for rapid identification of MTB, in conjunction with culture and drug-sensitivity testing. (GRADE 1B)
- We recommend the use of molecular tests in pulmonary smear-negative samples, always in conjunction with culture and drug-sensitivity testing. (GRADE 1B)
- When individuals present with symptoms suggestive of tuberculosis, we recommend asking for any known TB contact among family members, colleagues and friends. (GPP)

### Diagnosis of active extra-pulmonary TB

---

- We recommend sending CSF samples for TB molecular tests and conventional microscopy and culture for the diagnosis of TB meningitis. (GRADE 1C)
- We recommend performing microscopy and obtaining cultures for mycobacteria on respiratory samples (induced sputum/BAL) in individuals with suspected pleural TB, even in the absence of obvious lung parenchymal involvement. (GRADE 1B)
- We recommend obtaining material for microscopy and culture, as well as histology in combination with molecular biological techniques, for diagnosis of extra-pulmonary TB. (GPP)

### Diagnosis of multidrug-resistant TB infection

---

- We recommend the routine use of molecular techniques, in addition to phenotypic drug susceptibilities, in order to achieve rapid detection of at least rifampicin resistance in patients' samples. (GRADE 1C)
- We recommend that individuals with positive molecular tests for rifampicin resistance should be assumed to have MDR/XDRTB and managed in conjunction with a designated MDR centre. (GPP)

### Diagnosis of latent TB infection

---

- We recommend testing HIV-positive individuals from high- and medium-TB-incidence countries for LTBI, including pregnant women, regardless of their CD4 cell count and receipt of ART, with particular attention to those with newly diagnosed HIV or who have recently been exposed to TB. (GRADE 1B)
- We recommend testing HIV-positive individuals from low-incidence countries for LTBI if they have additional TB risk factors. (GRADE 1B)
- Prior to testing and providing treatment for LTBI, we recommend excluding active TB, by addressing presence of TB symptoms and signs and, where appropriate, conducting investigations (e.g. radiology). (GRADE 1A)
- We suggest that, in the UK setting, IGRA rather than TST should be used when testing HIV-positive individuals for LTBI. (GRADE 2C)
- The IGRA should be repeated if the first result is indeterminate or borderline. (GPP)
- We do not recommend the use of IGRA or TST in the diagnosis, or exclusion, of active TB. (GPP)

### Treatment of latent TB infection

---

- We recommend treatment for LTBI for at-risk individuals with a positive IGRA in whom active TB has been excluded by clinical assessment and chest radiography. (GRADE 1B)
- If a first and repeat IGRA are either indeterminate or borderline, the clinician should use clinical judgement when deciding whether to offer treatment for LTBI. (GPP)

- We recommend offering testing for, and treatment of, LTBI for all HIV-positive individuals who are close contacts of people with infectious TB as per NICE guidelines. (GRADE 1B)
- We recommend treatment of LTBI for all HIV-positive individuals with a positive IGRA who are receiving cancer chemotherapy or prolonged duration of high-dose corticosteroids (20 mg od prednisolone, or equivalent, for 2 months or longer) where the prognosis is >1 year, as per NICE guidelines. (GRADE 1B)
- We recommend treatment for LTBI with: 6 months of isoniazid plus pyridoxine; or 3 months of isoniazid plus rifampicin plus pyridoxine. (GRADE 1A)

## Treatment of active drug-sensitive TB

---

- We recommend daily administration of standard TB therapy in those with drug-sensitive TB. (GRADE 1A)
- We recommend that where effective ART necessitates the use of a PI/r, rifampicin is substituted with rifabutin. (GRADE 1C)
- We recommend that individuals with TB meningitis receive corticosteroids. (GRADE 1A)
- We recommend using fixed-dose combination tablets (rifampicin/isoniazid, rifampicin/isoniazid/pyrazinamide and rifampicin/isoniazid/pyrazinamide/ethambutol) wherever possible, in order to enhance treatment adherence. (GPP)
- We recommend against routine testing for vitamin D deficiency and/or supplementation of vitamin D. (GRADE 1A)

## Management of treatment failure and relapse

---

- We recommend that a microbiological diagnosis is pursued in all individuals with treatment failure and relapse. (GPP)
- We recommend that individuals with treatment failure/relapse are managed in conjunction with centres of expertise and receive, as per WHO recommendations, at least two or three new drugs from different classes while awaiting the results of drug susceptibility tests. (GPP)

## Management of drug-resistant TB

---

- We recommend, in individuals who are found to be infected with isoniazid mono-resistant isolates, a regimen of rifampicin, ethambutol, moxifloxacin and pyrazinamide for 2 months followed by rifampicin and moxifloxacin for 4–7 months. (GRADE 1B)
- We recommend that all individuals with rifamycin- (including multidrug-) resistant TB are managed in conjunction with centres of expertise in the management of drug-resistant TB. (GPP)
- We recommend that all individuals with rifampicin-resistant or multidrug-resistant TB who are not already on ART initiate ART as soon as they are stable and TB treatment is tolerated. (GRADE 1B)

## Directly observed therapy (DOT)

---

- We recommend individualised, enhanced patient-centred care plans for all patients. Some of these may include DOT and video observed therapy (VOT). (GPP)
- We recommend against the routine use of DOT and VOT. (GRADE 1A)

## Choice of antiretroviral treatment in individuals not on ART

---

### *When to start ART*

- We recommend that all individuals with TB should start ART as soon as is practicable, and within 8–12 weeks of the TB diagnosis. (GRADE 1A)
- We recommend that individuals with a CD4 cell count <50 cells/mm<sup>3</sup> start ART as soon as is practicable and within 2 weeks. (GRADE 1A)
- We recommend against the early initiation (<2 months) of ART in individuals with CNS TB. (GRADE 1A)

## What ART to start

- We recommend efavirenz (standard dose) in combination with tenofovir (TDF) and emtricitabine as first-line ART. (GRADE 1B)
- We suggest that raltegravir can be used for individuals in whom efavirenz is contraindicated. (GRADE 2B)
- We recommend that rifabutin is used instead of rifampicin where effective ART necessitates the use of ritonavir-boosted protease inhibitors. (GRADE 1C)
- We recommend against the use of fixed-dose combinations containing tenofovir alafenamide (TAF), when co-administered with rifampicin or rifabutin. (GRADE 1D)
- We recommend against the use of nevirapine in ART-naïve individuals with TB treated with rifampicin. (GRADE 1B)

## Choice of antiretroviral treatment in individuals on established ART

---

- We recommend that individuals who develop TB on ART with undetectable HIV viral loads do not interrupt their ART. (GRADE 1A)
- We recommend that rifampicin-based TB treatment is used in individuals whose established ART consists of efavirenz (GRADE 1B), nevirapine (GRADE 2C), or raltegravir (GRADE 2C) plus two NRTIs.
- We recommend that rifabutin is used instead of rifampicin where established ART necessitates use of ritonavir. (GRADE 1C)

## Drug interactions and toxicities

---

- We recommend undertaking a complete medicines reconciliation prior to starting treatment for either TB or HIV. (GPP)
- We recommend using prescribing resources (e.g. [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org), or <http://hivclinic.ca/drug-information/drug-interaction-tables/>) to screen for DDIs in all individuals with TB/HIV co-infection. (GPP)

## IRIS (IRIS diagnosis/management)

---

- We recommend the use of corticosteroids tapered over 4–6 weeks in symptomatic IRIS. (GRADE 1C)
- We recommend that in recurrent IRIS, and in complex cases, advice is sought from centres with experience in managing this syndrome. (GPP)

## Pregnancy and breastfeeding

---

- We recommend that pregnant and breastfeeding women with drug-sensitive TB are treated with standard first-line anti-tuberculous therapy. (GRADE 1C)

## Prevention and control of transmission

---

- We recommend that all hospitals and HIV units have a TB infection control plan, which includes adequate protection of healthcare workers and other contacts. (GRADE 1B)

## Notification/tracing of contacts

---

- We recommend that once a person has been diagnosed with active TB, the diagnosing physician should inform relevant colleagues so that the need for contact tracing can be assessed without delay. Contact tracing should not be delayed until notification. (GRADE 1B)
- We recommend screening the close contacts of any person with pulmonary or laryngeal TB. (GRADE 1B)

## 3 Introduction

---

These guidelines update the previously published BHIVA guidelines on the treatment of TB/HIV co-infection from 2011 [1] and are designed to provide a clinical framework applicable to adults in the UK co-infected with HIV and TB. They do not include management of HIV-positive children with TB. The guidance is based on the evidence available, although some recommendations necessarily rely on expert opinion until further data become available.

These guidelines should be used in conjunction with:

- National Institute for Health and Care Excellence (NICE): Tuberculosis. Available at: [www.nice.org.uk/guidance/ng33](http://www.nice.org.uk/guidance/ng33) [2];
- British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 [3];
- World Health Organization 2016 guidelines for the treatment of drug-resistant tuberculosis: [www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/](http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/) [4].

The World Health Organization reported the following in 2015 [5]:

- An estimated 10.4 million people developed TB and 1.4 million died of TB, with an estimated 3.5 million cases and 496,000 TB deaths among women, and an estimated 950,000 cases and 210,000 deaths among children.
- An estimated 1.2 million (11%) of the 10.4 million people who developed TB in 2015 were HIV positive.
- 1.4 million HIV-negative persons died from the disease and there were 390,000 deaths among HIV-positive people.
- An estimated 510,000 women died as a result of TB, more than one-third of whom were HIV positive.
- Although the number of TB deaths fell by 22% between 2000 and 2015, TB remained one of the top 10 causes of death worldwide.

The incidence of TB in England is higher than in most western European countries [6]. While it was declining during most of the 20<sup>th</sup> century, a steady increase was observed from the late 1980s to 2005.

The annual incidence rates of TB among adults living with diagnosed HIV in England and Wales declined from 17 per 1000 (420/23,990) in 2008 to 4.3 per 1000 (300/68,350) in 2011 [7]. This trend is largely due to a decline in new HIV diagnoses among men and women born in countries of sub-Saharan Africa where the prevalence of both HIV and TB is high, as well as to an increase in total number of people living with HIV [8].

TB incidence varies by demographic characteristics with rates among people born outside the UK of 7.7 per 1000 population (in 2011), women (6.7), those aged 25–39 years (10.5) and people of black African ethnicity (7.7).

The risk of developing TB is estimated to be between 26 and 31 times greater in people living with HIV than among those without HIV infection. Thus, all individuals with TB, regardless of their perceived risk of HIV infection, should be offered an HIV test.

In HIV co-infection, the clinical and radiographic presentation of TB may be atypical. Compared with the immune-competent population, TB/HIV-infected individuals with active pulmonary TB are more likely to have normal chest radiographs or to have sputum that is smear negative but culture positive [9,10] (see Section 5 and Appendix 3).

The clinician caring for HIV-infected individuals therefore needs to have a high index of suspicion for TB in symptomatic individuals, especially those who have lived in TB-endemic parts of the world. As the investigation and treatment of both TB and HIV infection is complex, it is mandatory to involve specialists in HIV, respiratory and/or infectious diseases.

### 3.1 References

---

1. Pozniak AL, Coyne KM, Miller RF *et al.* British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. *HIV Med* 2011; **12**: 517–524.
2. NICE. *Tuberculosis. NICE guideline [NG33]*. 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).
3. Waters L, Ahmed N, Angus A *et al.* *British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. 2016 Interim update*. 2015. Available at: <http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf> (accessed November 2017).
4. World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. 2016.
5. World Health Organization. Global tuberculosis report 2015. 2015.
6. European Centre for Disease Prevention and Control. *Tuberculosis surveillance and monitoring in Europe 2014*. 2014. Available at: <https://ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2014> (accessed January 2018).
7. Public Health England. *HIV in the United Kingdom: 2014 Report*. London: PHE; 2014. Available at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/401662/2014\\_PHE\\_HIV\\_annual\\_report\\_draft\\_Final\\_07-01-2015.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf) (accessed June 2015).
8. Rice B, Elford J, Yin Z *et al.* Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales. *AIDS* 2013; **27**: 1151–1157.
9. Ackah AN, Coulibaly D, Digbeu H *et al.* Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. *Lancet* 1995; **345**: 607–610.
10. Chaisson RE SG, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. *Am Rev Respir Dis* 1987; **136**: 570–574.

## 4 Aims of TB treatment

---

Treatment of TB benefits the individual and also the community. The aims of treatment are [1]:

- To cure the patient and restore quality of life and productivity;
- To prevent death from active TB or its late effects;
- To prevent relapse of TB;
- To reduce transmission of TB to others;
- To prevent the development and transmission of drug resistance.

### 4.1 References

---

1. World Health Organization. *Guidelines for treatment of tuberculosis. 4th edn.* 2010. Available at: <http://www.who.int/tb/publications/2010/9789241547833/en/> (accessed March 2017).

## 5 Diagnosis of active TB/HIV (diagnostic tests)

---

### 5.1 Pulmonary TB diagnosis in HIV

---

- We recommend performing microscopy for acid-fast bacilli (AFB) on respiratory samples (sputum, induced sputum or BAL), followed by molecular testing using CBNAAT (cartridge-based NAAT), e.g. Xpert MTB/RIF, for rapid identification of MTB, in conjunction with culture and drug-sensitivity testing. (GRADE 1B)
- We recommend the use of molecular tests in pulmonary smear-negative samples, always in conjunction with culture and drug-sensitivity testing. (GRADE 1B)
- When individuals present with symptoms suggestive of tuberculosis, we recommend asking for any known TB contacts among family members, colleagues and friends. (GPP)

#### 5.1.1 Rationale

Microscopic smears of body fluids remain an essential part of TB diagnosis. The quality of any investigation is related to the quality of the specimen and the clinical detail provided within the request. There must therefore be close liaison with the mycobacterial laboratory. Results should be available within 1 working day.

Use of molecular biology allows for early identification of mycobacteria and of genotypic (rifampicin/isoniazid) drug susceptibility. The Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is an automated molecular test for *M. tuberculosis* identification and *rpoB* mutations conferring resistance to rifampicin. It is very specific (99%) and its sensitivity for smear-positive, culture-positive TB approaches 98%, compared with microscopy, which has a sensitivity of 65% [1]. The sensitivity for RIF resistance, is a little lower (95%) than the sensitivity for MTB identification (see Appendix 3).

In smear-positive samples its use can allow rapid confirmation that AFB are not *M. tuberculosis*, potentially avoiding unnecessary treatment and infection-control measures [2].

Despite the high sensitivity and specificity, molecular biology tests have to be performed together with cultures and phenotypic drug susceptibility testing. All specimens, even those negative for *M. tuberculosis* on polymerase chain reaction (PCR), still require culture because a negative PCR does not exclude *M. tuberculosis* and a positive PCR does not currently indicate the full drug-susceptibility profile [3,4].

The sensitivity and specificity of either IGRA (QTCF-GIT and T-SPOT.TB) in HIV-infected people is suboptimal when used alone to 'rule in' or 'rule out' active tuberculosis disease [5-8]. IGRA tests should not be used to diagnose or exclude active TB (see Appendix 3).

Identification of mycobacteria is performed at reference centres, and is based on morphology, growth and biochemical characteristics.

More rapid results are obtained from liquid media, which usually grow *M. tuberculosis* in 7–28 days. Drug-susceptibility tests are usually available within 10–21 days of the laboratory receipt of isolates and are performed using standard assays.

### 5.2 Extra-pulmonary TB diagnosis (EPTB)

---

#### 5.2.1 TB of the CNS

- We recommend sending CSF samples for TB molecular tests, conventional microscopy and culture for the diagnosis of TB meningitis. (GRADE 1C)

### 5.2.2 Rationale

The commonest presentation of tuberculosis in the CNS is tuberculous meningitis (TBM), which is the most severe form of TB with the highest mortality (between 20% and 50%) and morbidity, as diagnosis and treatment are often delayed [9].

Less commonly it can manifest as tuberculous encephalitis, intracranial tuberculomas, or tuberculous brain abscess(es) [9].

Early diagnosis is challenging due to the non-specific symptoms of TBM, such as fever, headache and vomiting, with gradual onset and duration, often lasting for weeks. Meningism, with or without focal neurological deficits, behavioural changes and alterations in consciousness are also features of TBM.

The main investigations are cranial imaging (MRI) and lumbar puncture for CSF analysis.

Significant CSF findings in TBM include a mainly mononucleate cell (lymphocytic predominant), pleocytosis in 60–85% of patients, in which the total white count ranges between 100 and 500 cells/mm<sup>3</sup>. Low CSF glucose levels (usually less than 2.5mmol/L) and a high protein, typically between 1 and 5 g/L, are also suggestive of TBM.

Identification of *M. tuberculosis* in CSF by culture remains the 'gold standard', but has a limited sensitivity (ranging between 10% and 60%). Microscopy with Ziehl–Neelsen staining for AFB detection has a low sensitivity in the CSF (range 10–60%), due to the small number of tubercle bacilli usually present. Large volumes (minimum 6 mL) of CSF should be examined to enhance the sensitivity [10,11].

The World Health Organization recommendation is to use Xpert MTB/RIF as the preferred initial test for diagnosis of TB meningitis over conventional tests (see Appendix 3).

Adenosine deaminase (ADA) (a predominant T lymphocyte enzyme, which catalyses the conversion of adenosine and deoxyadenosine to inosine and deoxyinosine, respectively) measurement can also be of use in the diagnosis of TB meningitis. Levels in CSF are significantly elevated in TBM with a sensitivity and specificity ranging from 60–90% and 80–90%, respectively [12]. However, the ADA assay has not been standardised and the 'cut-off' level that defines a positive result has not been determined, and consequently it is not recommended for routine analysis of TB meningitis [13,14].

## 5.3 TB pleuritis

- In addition to performing pleural fluid and tissue analysis, we recommend performing microscopy and obtaining cultures for mycobacteria on respiratory samples (induced sputum/BAL) in individuals with suspected pleural TB, even in the absence of obvious lung parenchymal involvement [15]. (GRADE 1B)

### 5.3.1 Rationale

Where HIV is endemic, TB pleuritis is the most common cause of a lymphocytic effusion, and thought to result from primary infection in 30% of patients [16].

In individuals with a suspected TB pleural effusion it is important to obtain cultures on pulmonary (generally sputum or bronchoscopic) samples, even in the absence of obvious parenchymal involvement, as in individuals with normal underlying lung parenchyma on chest radiography, the yield of sputum culture in induced samples approaches 55% [15].

The diagnosis of TB pleuritis is also made by detection of *M. tuberculosis* in pleural fluid or pleural biopsy specimens, or by assumption if *M. tuberculosis* is identified in sputum and there is co-existent pleural effusion, either by microscopy and/or culture, or the histological demonstration in the pleura of caseating granulomas together with AFB.

Microscopy for AFB in the pleural fluid can identify *M. tuberculosis* in approximately 20% of HIV-infected individuals, though the yield can be up to 50% [17] if the patient's CD4 cell count is less than 100 cells/mm<sup>3</sup> [17,18].

TB PCR has a low sensitivity for diagnosis of pleural TB. A pooled analysis of data from 20 studies that assessed the use of pleural fluid molecular diagnostic tests showed a high specificity (97% for commercial and 91% for in-house tests), but a generally poor and variable sensitivity (62% for commercial and 76.5% for in-house tests) [4].

Another useful diagnostic tool is the measurement and quantification of ADA in pleural fluid. Individuals who present with a lymphocytic predominant exudative pleural effusion and raised ADA level have a high probability of having pleural TB (see Appendix 3).

## 5.4 Lymph node TB and disseminated TB

---

- We recommend obtaining material for microscopy and culture, as well as histology in combination with molecular biological techniques, for diagnosis of extra-pulmonary TB. (GPP)

### 5.4.1 Rationale

Data on the accuracy of the use of molecular biological tests for diagnosis of TB in non-respiratory specimens have been reported in two systematic reviews, which both support its use in diagnosis of EPTB [19,20] (see Appendix 3).

The urine lateral flow lipoarabinomannan (LF-LAM) assay is a point-of-care (POC) test for active TB (AlereDetermine TB LAM Ag, Alere Inc., Waltham, MA, USA). The test detects lipoarabinomannan (LAM), a lipopolysaccharide present in mycobacterial cell walls, released from metabolically active or degenerating bacterial cells. This antigen appears to be present only in people with active TB disease. The advantages of the test are its simplicity and speed of use, lack of instrumentation, low cost and its implementation at the point of care. Its sensitivity is highest in those individuals with a CD4 cell count  $<100$  cells/mm<sup>3</sup> [21].

It represents a useful adjunctive diagnostic for those with CD4 cell counts below 100 cells/mm<sup>3</sup> and in those presenting seriously ill with an unknown cause.

## 5.5 Cytopathology (lymph nodes, lung aspirate, focal lesions)

---

The cytopathological diagnosis of TB is based on finding acid and alcohol-fast bacilli (AFB) on Ziehl–Neelsen (ZN) staining of tissue or a cytological preparation (e.g. a lymph node aspirate). Supplementary supportive evidence is the finding of macrophage granulomas with or without necrosis.

The finding of AFB in a cytopathological specimen should be critically interpreted in the context of a patient's presentation, their imaging findings and results from other laboratory investigations. It is important to precisely identify AFB using culture and molecular diagnostic techniques.

## 5.6 Histopathology

---

The classical lesions of TB include epithelioid cell granulomas with or without Langhans giant cells and caseation necrosis, and AFB. Other diseases, infectious and non-infectious, have similar granuloma morphology as TB, and fungal stains must always be undertaken to exclude mycosis (e.g. histoplasmosis) as the relevant agent.

If TB is diagnosed histopathologically, but standard treatment appears ineffective, non-tuberculous mycobacteria should be considered. Other differential diagnoses that can mimic TB include: sarcoidosis, histoplasmosis, nocardiosis, leishmaniasis, granulomatous reaction to local tumour, common variable immunodeficiency syndromes, vasculitis syndromes, autoimmune diseases, and Gram-negative infections (e.g. brucellosis, melioidosis).

In difficult cases, multidisciplinary consultation is invaluable, where all the information – clinical, radiological, pathological, molecular diagnostics and results of treatment – can be critically reviewed.

Because the presence of granulomas is regarded as typical of TB, differential diagnoses should be considered, especially if response to treatment is not progressing as expected.

## 5.7 Diagnosis of multidrug-resistant TB

---

- We recommend the routine use of molecular techniques, in addition to phenotypic drug sensitivities, to achieve rapid detection of at least rifampicin resistance in patients' samples. (GRADE 1C)
- We recommend that individuals with positive molecular tests for rifampicin resistance should be assumed to have MDR/XDR TB and managed in conjunction with a designated MDR centre. (GPP)

### 5.7.1 Rationale

- *MDR TB definition*: resistance to at least isoniazid and rifampicin.
- *Pre-XDR TB definition*: resistance to isoniazid and rifampicin and either a fluoroquinolone or second-line injectable agent but not both.
- *XDR TB definition*: resistance to isoniazid and rifampicin and quinolones and at least one of the following injectable drugs: kanamycin, capreomycin, amikacin.

The number and proportion (1.6%) of TB cases with initial MDR/RRTB in England has been relatively stable since the peak in 2011 (89, 1.8%). The most frequent countries of birth of MDR/RRTB cases were India and Lithuania. Ten cases of XDR TB were notified in 2015, three of whom were born in the UK; this is the highest number of XDR TB cases notified in a single year in the last decade [22].

The presence of the following risk factors should always raise suspicion of possible drug-resistant TB:

- Previous TB treatment;
- Contact with MDR/XDR TB index case;
- Birth, travel or work in settings with very high MDR/XDR TB prevalence (as defined by Public Health England);
- History of poor adherence to previous TB treatment regimens;
- No clinical improvement on standard TB therapy and/or sputum remains 'smear' positive after 2 months of TB therapy or remains culture positive at 3 months;
- Homelessness/hostel living and in some countries recent/current incarceration.

Molecular tests for rifampicin resistance are useful, especially when MDR TB is suspected (e.g. a recent immigrant from an area with a high prevalence of rifampicin-resistant disease), as a large proportion of RIF-resistant strains have INH resistance as well [23] (see Appendix 3).

## 5.8 References

---

1. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. *J Clin Microbiol* 2011; **49**: 4138–4141.
2. Steingart KR, Schiller I, Horne DJ *et al*. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 2014; **1**: CD009593.
3. American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop. *Am J Respir Crit Care Med* 1997; **155**: 1804–1814.
4. Dinnes J, Deeks J, Kunst H *et al*. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. *Health Technol Assess* 2007; **11**: 1–196.
5. Chen J, Zhang R, Wang J *et al*. Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systematic review and meta-analysis. *PLoS One* 2011; **6**: e26827.
6. Cattamanchi A, Smith R, Steingart KR *et al*. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; **56**: 230–238.

7. Metcalfe JZ, Everett CK, Steingart KR *et al.* Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. *J Infect Dis* 2011; **204 Suppl 4**: S1120–1129.
8. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. *PLoS One* 2012; **7**: e32482.
9. Rock RB, Olin M, Baker CA *et al.* Central nervous system tuberculosis: pathogenesis and clinical aspects. *Clin Microbiol Rev* 2008; **21**: 243–261, table of contents.
10. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. *Lancet Neurol* 2013; **12**: 999–1010.
11. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. *J Clin Microbiol* 2004; **42**: 378–379.
12. Thwaites GE. Advances in the diagnosis and treatment of tuberculous meningitis. *Curr Opin Neurol* 2013; **26**: 295–300.
13. Tuon FF, Higashino HR, Lopes MI *et al.* Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis. *Scand J Infect Dis* 2010; **42**: 198–207.
14. Ho J, Marais BJ, Gilbert GL, Ralph AP. Diagnosing tuberculous meningitis - have we made any progress? *Trop Med Int Health* 2013; **18**: 783–793.
15. Conde MB, Loivos AC, Rezende VM *et al.* Yield of sputum induction in the diagnosis of pleural tuberculosis. *Am J Respir Crit Care Med* 2003; **167**: 723–725.
16. Diacon AH, Van de Wal BW, Wyser C *et al.* Diagnostic tools in tuberculous pleurisy: a direct comparative study. *Eur Respir J* 2003; **22**: 589–591.
17. Heyderman RS, Makunike R, Muza T *et al.* Pleural tuberculosis in Harare, Zimbabwe: the relationship between human immunodeficiency virus, CD4 lymphocyte count, granuloma formation and disseminated disease. *Trop Med Int Health* 1998; **3**: 14–20.
18. Luzze H, Elliott AM, Joloba ML *et al.* Evaluation of suspected tuberculous pleurisy: clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda. *Int J Tuberc Lung Dis* 2001; **5**: 746–753.
19. Denkinger CM, Schumacher SG, Boehme CC *et al.* Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2014; **44**: 435–446.
20. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. *BMC Infect Dis* 2014; **14**: 709.
21. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. *Lancet Infect Dis* 2012; **12**: 201–209.
22. Public Health England. *Tuberculosis in England 2016 report: presenting data to end of 2015*. 2016. Available at: <http://www.gov.uk/government/publications/tuberculosis-in-england-annual-report> (accessed March 2017).
23. World Health Organization. *Global tuberculosis report 2016*. 2016. Available at: [http://www.who.int/tb/publications/global\\_report/en/](http://www.who.int/tb/publications/global_report/en/) (accessed March 2017).

## 6 Diagnosis and treatment of latent TB in HIV-infected adults

---

### 6.1 Diagnosis of latent TB

---

- We recommend testing HIV-positive individuals from high- and medium-TB-incidence countries for LTBI, including pregnant women, regardless of their CD4 cell count and receipt of ART, with particular attention to those with newly diagnosed HIV or who have recently been exposed to TB. (GRADE 1B)
- We recommend testing HIV-positive individuals from low-incidence countries for LTBI if they have additional TB risk factors. (GRADE 1C)
- Prior to testing and providing treatment for LTBI, we recommend excluding active TB, by addressing presence of TB symptoms and signs and, where appropriate, conducting investigations (e.g. radiology). (GRADE 1A)
- We suggest that, in the UK setting, IGRA rather than TST should be used when testing HIV-positive individuals for LTBI. (GRADE 2C)
- The IGRA should be repeated if the first result is indeterminate or borderline. (GPP)
- We do not recommend the use of IGRA or TST in the diagnosis, or exclusion, of active TB. (GPP)

#### 6.1.1 Rationale

In the UK, the majority of cases of TB result from reactivation of LTBI rather than recent transmission. Individuals with latent TB infection (LTBI) are at increased risk of developing active TB, especially if they are recently infected with *M. tuberculosis* or immunocompromised [1]. HIV-positive individuals from high TB-incidence countries, especially those from sub-Saharan Africa, often present with TB as the first manifestation of immunosuppression, and mortality among HIV-positive persons with TB remains high [2]. We define high and medium TB incidence as  $\geq 151/100,000$  and  $40\text{--}150/100,000$  person years, respectively [3]. (See [4,5] for up-to-date TB incidence by country.) LTBI testing for new entrants to the UK from high TB-incidence countries is an effective and cost-effective public health intervention [6] and is recommended by NICE [3]. WHO guidelines for low tuberculosis-burden countries [7] advise testing for LTBI in all HIV-positive individuals. However, this approach has recently been shown unlikely to be cost-effective in the UK [8].

The risk of progression to active TB in the general population is highest within the first 2–3 years following *M. tuberculosis* infection and HIV-positive individuals with LTBI are much more likely to progress to active TB than HIV-negative individuals [9]. Increased incidence of active TB is associated with low CD4+ cell counts, including while on ART, and shorter time on ART [10–13].

Long-term successful ART substantially reduces the risk of TB among HIV-positive individuals, although it should be remembered that in populations from high TB-incidence countries, such as those of sub-Saharan Africa, the background risk of TB (irrespective of HIV co-infection) is already high [2] (see Table 6.1).

A positive IGRA in an individual with no clinical or radiological evidence of active TB constitutes a diagnosis of LTBI. Before testing for or treating LTBI, active TB should be excluded with a detailed history and examination. The advantages of IGRAs include the practical benefit of a single blood test with no need for patient recall to read the result. They are more costly than TST, although the savings may offset this in, for instance, healthcare worker time and possible better specificity leading to fewer individuals being treated for LTBI [6,14].

NICE recommends testing for LTBI with an IGRA and concurrent TST in HIV-positive individuals [3]. However, in view of operational and cost disadvantages of TST, a reduced sensitivity among those with low CD4+ cell counts, and false-positive results due to prior BCG vaccination and exposure to non-tuberculous mycobacteria, plus limited data comparing strategies of using IGRA and TST to identify LTBI among those with low CD4+ cell counts, we recommend the sole use of IGRA in a UK setting (see Appendix 4).


Some individuals born in low-incidence countries, including the UK, will be at greater risk of developing TB than others. We recommend considering testing for and treating LTBI in those from low-incidence countries (for example UK-born) who have additional risk factors such as exposure to a known TB case (which should be checked through routine contact tracing); diabetes mellitus; travel to or periods of time (we suggest >12 months) spent consecutively in higher-incidence countries [3]. Particular additional factors of relevance to HIV-positive individuals include: a history of working in medical settings in endemic areas; injecting drug use; stage 4/5 chronic kidney disease; receipt of chemotherapy for malignancy; immunosuppression following organ transplantation; and biological disease modifiers for inflammatory conditions.

In pregnant women newly diagnosed with HIV, we recommend testing and treating LTBI in the same way as non-pregnant individuals, including use of chest radiography, if clinically indicated.

In making this recommendation, we have considered the risk of toxicity from treatment for LTBI. Hepatotoxicity in particular is associated with other co-existing risk factors (see below).

We suggest using an algorithm (Figure 6.1) similar to that proposed by the WHO for use in excluding active TB [15]. Other investigations may be necessary, for example chest radiography or lymph node biopsy (if lymphadenopathy is detected clinically, or through imaging). It is important to consider the possibility of subclinical TB prior to starting ART because of the risk of IRIS, particularly among those with low CD4 cell counts [16]. (See Section 12 and Appendix 7.)

**Figure 6.1.** Algorithm for LTBI diagnosis and treatment



**Table 6.1.** TB risk factors

<b>Risks for TB</b>	
Origin from high/medium TB-incidence country	
HIV-positive individuals with CD4+ cell counts <200 cells/mm <sup>3</sup>	
Recent exposure to a known TB case	
Diabetes mellitus Stage 4/5 chronic kidney disease Receipt of chemotherapy for malignancy; immunosuppression following organ transplantation; biological disease modifiers for inflammatory conditions	
Travel to or periods of time spent consecutively in higher-incidence countries	Duration of travel to be considered if >12 months
History of working in medical settings in endemic areas	
Injecting drug use	

## 6.2 Treatment of latent TB infection

- We recommend treatment for LTBI for those at-risk individuals with a positive IGRA, in whom active TB has been excluded by clinical assessment and chest radiography. (GRADE 1B)
- If a first and repeat IGRA are either indeterminate or borderline, the clinician should use clinical judgement when deciding whether to offer treatment for LTBI. (GPP)
- We recommend offering testing for, and treatment of, LTBI for all HIV-positive individuals who are close contacts of people with infectious TB, as per NICE guidelines. (GRADE 1B)
- We recommend treatment of LTBI in all HIV-positive individuals with a positive IGRA who are receiving cancer chemotherapy or prolonged duration of high-dose corticosteroids (20 mg od prednisolone, or equivalent, for 2 months, or longer) where the prognosis is >1 year, as per NICE guidelines. (GRADE 1B)
- We recommend treatment for LTBI with: 6 months of isoniazid plus pyridoxine; or 3 months of isoniazid plus rifampicin plus pyridoxine. (GRADE 1A)

### 6.2.1 Rationale

There have been many short-term controlled trials in HIV-positive individuals showing a protective effect of treatment for LTBI with an efficacy ranging from 60 to 90% (see Appendix 4).

Several studies have compared different regimens for treating LTBI [17-19] and no difference in efficacy was found. We concur with NICE recommendations [3] and recommend either:

1. Daily isoniazid with pyridoxine for 6 months
2. Daily isoniazid (with pyridoxine) and rifampicin for 3 months

Other regimens that might be considered, depending on individual circumstances and concomitant medications, and which have evidence for equivalent efficacy include:

3. Isoniazid and rifampicin (with pyridoxine) twice weekly for 3 months [17].

Regimens 2 and 3 have been shown to be equivalent to regimen 1 in terms of TB-free survival [17] and in the prevention of incident TB after treatment and hepatotoxicity of grade 3 or above [18,19]. A regimen of rifampicin plus pyrazinamide has been shown to be effective in preventing active TB, but there is evidence that

pyrazinamide-containing regimens cause more hepatotoxicity than isoniazid alone and they are therefore not recommended [19-21]. Care must be taken to avoid drug–drug interactions with ART.

Mild, non-specific hepatotoxicity occurs in up to 20% of individuals taking isoniazid, but most of this is subclinical and evidenced only by mildly elevated serum aminotransferases (usually <100 IU/L) [22]. During isoniazid therapy for LTBI, clinical symptomatic hepatotoxicity is rare (<1%) but can be fatal, particularly if associated with other factors, for example alcohol, increased age or concurrent liver disease [23,24].

Most hepatotoxicity is self-limiting and isoniazid can be continued with clinical and laboratory monitoring. The risk of severe (ACTG grade 3 or above) hepatotoxicity associated with isoniazid therapy for LTBI is 0.1–0.3% according to different studies [25,26]. Rifampicin-containing regimens should also be prescribed with caution due to potential drug–drug interactions.

When considering treatment for LTBI, the potential benefit needs to be carefully balanced against the risk of drug-related adverse events. Individuals treated for LTBI should be informed of symptoms of hepatotoxicity, such as anorexia, nausea, vomiting, abdominal discomfort, persistent fatigue or weakness, dark-coloured urine, pale stools or jaundice. Those experiencing these symptoms should be advised to contact their healthcare providers, and to stop treatment immediately if there is a delay in doing so.

### 6.3 Drug-resistant TB after treatment of LTBI

---

Studies of isoniazid treatment for LTBI have included the risk of isoniazid-resistant active TB as a secondary outcome. Although there are theoretical concerns that widespread isoniazid monotherapy might speed the emergence of drug-resistant TB [27], evidence from trials has shown no significant association between anti-tuberculous drug resistance and prior use of isoniazid and/or rifamycins for LTBI [17,28,29].

### 6.4 Secondary prophylaxis after treatment for active TB and longer-term isoniazid preventive therapy

---

Studies in areas of high TB incidence have shown that isoniazid prophylaxis post-treatment achieves short-term reductions in rates of TB [30,31] and that long-term isoniazid therapy (36 months in trials) reduces TB incidence [32,33] among HIV-positive individuals. Such a strategy may in fact prevent reinfection, which is more common than true reactivation in such settings [34]. For maximum benefit the isoniazid would need to be continued long-term, or at least until CD4+ cell count had substantially risen on ART, and there are no data to support such an approach, particularly from lower TB-incidence settings.

It is clear that ART protects against TB. It should be initiated if not already in place, and continued, for those with active and latent TB (see Section 9 and Appendix 8).

Post-treatment continuation of TB prophylaxis is therefore not recommended in the UK setting, but ART should be continued.

### 6.5 Treatment of LTBI in individuals exposed to drug-resistant TB

---

For HIV-positive individuals with a history of exposure to drug-resistant TB (resistant to one or more first-line drugs), there are limited data to support any particular course of action. To help management of such cases an individualised management plan might be formulated from collaboration between the individual, their HIV physician, a specialist in the management of drug-resistant TB, and public health services. Options include: inform and advise the patient regarding early presentation with any symptoms of possible TB; use a treatment regimen for LTBI to which the source patient's isolate is considered to be susceptible; use of standard LTBI regimens if there is thought to have been pre-existing LTBI before the contact with drug-resistant disease occurred.

## 6.6 References

---

1. Public Health England. *Tuberculosis in England. 2015 report*. 2015. Available at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/564649/TB\\_annual\\_report\\_2015.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/564649/TB_annual_report_2015.pdf) (accessed January 2018).
2. Zenner D, Abubakar I, Conti S *et al*. Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. *Thorax* 2015; **70**: 566–573.
3. NICE. *Tuberculosis. NICE guideline [NG33]*. 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).
4. Public Health England. Tuberculosis (TB) by country: rates per 100,000 people. 2017. Available at: <http://www.gov.uk/government/publications/tuberculosis-tb-by-country-rates-per-100000-people> (accessed November 2017).
5. World Health Organization. Tuberculosis country profiles. Available at: <http://www.who.int/tb/country/data/profiles/en/> (accessed March 2017).
6. Pareek M, Watson JP, Ormerod LP *et al*. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. *Lancet Infect Dis* 2011; **11**: 435–444.
7. Getahun H, Matteelli A, Abubakar I *et al*. Management of latent *Mycobacterium tuberculosis* infection: WHO guidelines for low tuberculosis burden countries. *Eur Respir J* 2015; **46**: 1563–1576.
8. Capocci SS, J; Smith, C; Cropley, I; Bhagani, S; Morris, S; Abubakar, S; Johnson, M; Lipman, M;. Testing for TB in a contemporary UK HIV clinic –is it really worth it? *BHIVA*. 19–22 April 2016. Manchester, UK.
9. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. *AIDS Rev* 2002; **4**: 165–176.
10. Grant AD, Bansi L, Ainsworth J *et al*. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? *AIDS* 2009; **23**: 2507–2515.
11. Lawn SD, Myer L, Edwards D *et al*. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. *AIDS* 2009; **23**: 1717–1725.
12. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. *AIDS* 2005; **19**: 2109–2116.
13. Elzi L, Schlegel M, Weber R *et al*. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. *Clin Infect Dis* 2007; **44**: 94–102.
14. Campbell JR, Krot J, Elwood K *et al*. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants. *Mol Diagn Ther* 2015; **19**: 9–24.
15. World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015.
16. Meintjes G, Lawn SD, Scano F *et al*. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis* 2008; **8**: 516–523.
17. Martinson NA, Barnes GL, Moulton LH *et al*. New regimens to prevent tuberculosis in adults with HIV infection. *N Engl J Med* 2011; **365**: 11–20.
18. Sterling TR, Scott NA, Miro JM *et al*. Three months of weekly rifapentine and isoniazid for treatment of *Mycobacterium tuberculosis* infection in HIV-coinfected persons. *AIDS* 2016; **30**: 1607–1615.

19. Stagg HR, Zenner D, Harris RJ *et al.* Treatment of latent tuberculosis infection: a network meta-analysis. *Ann Intern Med* 2014; **161**: 419–428.
20. van Hest R, Baars H, Kik S *et al.* Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. *Clin Infect Dis* 2004; **39**: 488–496.
21. Gordin F, Chaisson RE, Matts JP *et al.* Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Bein Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. *JAMA* 2000; **283**: 1445–1450.
22. Scherer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. *Ann Intern Med* 1969; **71**: 1113–1120.
23. Grant AD, Mngadi KT, van Halsema CL *et al.* Adverse events with isoniazid preventive therapy: experience from a large trial. *AIDS* 2010; **24 Suppl 5**: S29–36.
24. Gray EL, Goldberg HF. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatotoxicity for patients receiving preventive therapy for latent tuberculosis infection. *Intern Med J* 2016; **46**: 281–287.
25. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. *JAMA* 1999; **281**: 1014–1018.
26. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. *Am J Respir Crit Care Med* 2003; **168**: 443–447.
27. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfecting populations. *Proc Natl Acad Sci U S A* 2006; **103**: 7042–7047.
28. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. *Emerg Infect Dis* 2006; **12**: 744–751.
29. van Halsema CL, Fielding KL, Chihota VN *et al.* Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. *AIDS* 2010; **24**: 1051–1055.
30. Fitzgerald DW, Desvarieux M, Severe P *et al.* Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. *Lancet* 2000; **356**: 1470–1474.
31. Churchyard GJ, Fielding K, Charalambous S *et al.* Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? *AIDS* 2003; **17**: 2063–2070.
32. Samandari T, Agizew TB, Nyirenda S *et al.* 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011; **377**: 1588–1598.
33. Swaminathan S, Menon PA, Gopalan N *et al.* Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. *PLoS One* 2012; **7**: e47400.
34. Sonnenberg P, Murray J, Glynn JR *et al.* HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. *Lancet* 2001; **358**: 1687–1693.

## 7 Treatment of active drug-sensitive TB

- We recommend daily administration of standard TB therapy in those with drug-sensitive TB. (GRADE 1A)
- We recommend that where effective ART necessitates the use of a boosted PI, rifampicin is substituted with rifabutin. (GRADE 1C)
- We recommend that individuals with TB meningitis receive corticosteroids. (GRADE 1A)
- We recommend using fixed-dose combination tablets (rifampicin/isoniazid, rifampicin/isoniazid/pyrazinamide and rifampicin/isoniazid/pyrazinamide/ethambutol) wherever possible, in order to enhance treatment adherence. (GPP)
- We recommend against routine testing for vitamin D deficiency and/or supplementation of vitamin D. (GRADE 1A)

### 7.1 Rationale

The treatment of drug-susceptible tuberculosis evolved through an international clinical trial programme to the current standard of care: short-course chemotherapy, consisting of 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol (intensive phase), followed by 4 months of rifampicin and isoniazid (continuation phase) (2RHZE/4RH) [1,2] (see Table 7.1).

**Table 7.1.** First-line anti-tuberculosis agents and standard dosing

Drugs	Daily dose
Isoniazid (H)	5 mg/kg Max 300 mg
Rifampicin (R)	10 mg/kg Max 600 mg
Pyrazinamide (Z)	25 mg/kg Max 2 g
Ethambutol (E)	15 mg/kg Max 1.5 g

Several recent attempts to shorten TB therapy to 4 months (for instance, by using fluoroquinolones) have proved unsuccessful with high relapse rates [3-6]. Intermittent administration of TB therapy should be avoided during the induction phase, as this strategy has been associated with acquired rifampicin resistance [7].

There is no evidence that individuals with disseminated TB should receive more prolonged therapy unless there is CNS involvement. Many clinicians use extended treatment regimens (up to 12 months, as per NICE guidance [8]) for central nervous system tuberculosis (i.e. tuberculous meningitis) even though 6–9 months may be sufficient.

Rifabutin is a rifamycin with similar activity as rifampicin against *M. tuberculosis* [9-11] although no trials have been conducted in individuals receiving ART. The main advantage of rifabutin is that it allows the co-administration of (ritonavir-boosted) protease inhibitors. (See Section 10 and Appendix 6).

Corticosteroids should be used as an adjunct to TB therapy to reduce the immune/inflammatory response to *M. tuberculosis* in those with meningitis. A randomised controlled clinical trial of individuals with tuberculous meningitis showed a 31% reduction in mortality among individuals who received adjunctive dexamethasone during the induction phase [12]. They can also be used in severe immune reconstitution inflammatory syndrome (see Section 12). The use of corticosteroids in HIV-positive individuals with pericarditis and pleurisy was associated with a significantly increased risk of HIV-associated diseases (Kaposi sarcoma and CMV disease [13,14]). Additionally, in individuals with pericarditis, 6 weeks of prednisolone did not reduce the risk of death, cardiac tamponade and constrictive pericarditis [15] and although corticosteroid use in individuals with pleurisy has been associated with more rapid resolution of pleural effusions and reduced pleural thickening, there was no effect on mortality, respiratory function or pleural adhesions [14]. We therefore recommend against the routine

use of corticosteroids in individuals with TB/HIV co-infection who do not have meningitis or severe IRIS; if clinically indicated, corticosteroids should be used at the lowest effective dose and for the shortest duration.

Mycobacterial disease may be due to non-tuberculous mycobacteria such as *M. avium* complex (MAC). Individuals with disseminated MAC tend to be profoundly immunosuppressed (CD4+ count <100 cells/mm<sup>3</sup> and/or concomitant opportunistic disease). Not infrequently, MAC disease is unmasked following the initiation of antiretroviral therapy. Smear AFB-positive specimens from individuals with MAC, rather than *M. tuberculosis*, would have negative molecular tests for *M. tuberculosis* DNA (see Appendix 3).

Individuals with severe immunodeficiency may benefit from the inclusion of rifabutin (instead of rifampicin) as well as clarithromycin or azithromycin in the empiric regimen to provide cover against MAC until culture results become available.

## 7.2 Interruptions of therapy

Anti-tuberculosis treatment interruptions can occur as a result of drug reactions and severe adverse events in HIV-associated TB. If the reason was poor adherence and the patient was on self-administered therapy, then supervised treatment should be considered. If the patient was already being managed with DOT/VOT, additional measures may be necessary to ensure adherence, for instance provision of transport, food and social services. See Table 7.2 for details on management of treatment interruptions.

**Table 7.2.** Management of treatment interruptions<sup>a</sup>. From [16]

Time point of interruption	Details of interruption	Approach
During intensive phase	Lapse is <14 days in duration	Continue treatment to complete planned total number of doses (as long as all doses are completed within 3 months)
	Lapse is ≥14 days in duration	Restart treatment from the beginning
During continuation phase	Received ≥80% of doses and sputum was AFB smear negative on initial testing in pulmonary disease	Further therapy may not be necessary
	Received ≥80% of doses and sputum was AFB smear-positive on initial testing, or disease extrapulmonary	Continue all doses until therapy is complete
	Received <80% of doses and cumulative lapse is <3 months in duration	Continue all doses until therapy is completed (full course), unless consecutive lapse is >2 months  If treatment cannot be completed within recommended time frame for regimen, restart therapy from the beginning (i.e. restart intensive phase, to be followed by continuation phase) <sup>b</sup>
	Received <80% of doses and lapse is ≥3 months in duration	Restart therapy from the beginning, new intensive and continuation phases (i.e. restart intensive phase, to be followed by continuation phase)

AFB: alcohol-acid fast bacilli

<sup>a</sup> According to expert opinion, patients who are lost to follow-up (on treatment) and brought back to therapy, with interim treatment interruption, should have sputum re-sent for AFB smear culture, and drug-susceptibility testing.

<sup>b</sup> The recommended time frame for regimen, in tuberculosis control programmes in the US and in several European countries, is to administer all of the specified number of doses for the intensive phase within 3 months and those for the 4-month continuation phase within 6 months, so that the 6-month regimen is completed within 9 months.

## 7.3 Investigations and monitoring

---

Prior to commencing TB therapy:

- HIV plasma load and CD4+ cell count
- Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT), bilirubin and alkaline phosphatase
- Serum creatinine and estimated glomerular filtration rate
- Platelet count
- Hepatitis B and C serology
- Visual acuity with Snellen chart and colour vision with Ishihara plates (before starting ethambutol).
- Many HIV/TB co-infected individuals have low 25-OH vitamin D concentrations. Several trials have failed to demonstrate a benefit from vitamin D supplementation in the majority of individuals [17-22]. We recommend against routine testing for vitamin D deficiency and/or supplementation of vitamin D.

HIV-infected individuals have more drug reactions, especially those with low CD4+ cell counts, and are more likely to be co-infected with hepatitis B and/or C than HIV-negative individuals. Furthermore, they may be starting concomitant antiretroviral and other therapies, all of which may cause liver enzyme elevation and/or hepatotoxicity. We suggest that liver function tests should be rechecked at 1–2 weeks. Individuals with pre-existing liver disease need close monitoring, for instance every 2 weeks for the first 2 months. Most physicians will see the patient 2 weeks after starting anti-tuberculosis therapy and then monthly until stable and 1–2 monthly until therapy has been completed.

## 7.4 References

---

1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. *Int J Tuberc Lung Dis* 1999; **3**: S231–279.
2. Menzies D, Benedetti A, Paydar A *et al.* Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. *PLoS Med* 2009; **6**: e1000146.
3. Gillespie SH, Crook AM, McHugh TD *et al.* Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. *N Engl J Med* 2014; **371**: 1577–1587.
4. Merle CS, Fielding K, Sow OB *et al.* A four-month gatifloxacin-containing regimen for treating tuberculosis. *N Engl J Med* 2014; **371**: 1588–1598.
5. Jawahar MS, Banurekha VV, Paramasivan CN *et al.* Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. *PLoS One* 2013; **8**: e67030.
6. Jindani A, Harrison TS, Nunn AJ *et al.* High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. *N Engl J Med* 2014; **371**: 1599–1608.
7. Narendran G, Menon PA, Venkatesan P *et al.* Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. *Clin Infect Dis* 2014; **59**: 1798–1804.
8. NICE. *Tuberculosis. NICE guideline [NG33]*. 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).
9. McGregor MM, Olliaro P, Wolmarans L *et al.* Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. *Am J Respir Crit Care Med* 1996; **154**: 1462–1467.
10. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. *Cochrane Database Syst Rev* 2007; CD005159.

11. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. *Tuber Lung Dis* 1994; **75**: 341–347.
12. Thwaites GE, Nguyen DB, Nguyen HD *et al.* Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N Engl J Med* 2004; **351**: 1741–1751.
13. Elliott AM, Luzze H, Quigley MA *et al.* A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. *J Infect Dis* 2004; **190**: 869–878.
14. Engel ME, Matchaba PT, Volmink J. Corticosteroids for tuberculous pleurisy. *Cochrane Database Syst Rev* 2007; CD001876.
15. Mayosi BM, Ntsekhe M, Bosch J *et al.* Prednisolone and *Mycobacterium indicus pranii* in tuberculous pericarditis. *N Engl J Med* 2014; **371**: 1121–1130.
16. Nahid P, Dorman SE, Alipanah N *et al.* Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis* 2016; **63**: e147–e195.
17. Martineau AR, Timms PM, Bothamley GH *et al.* High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. *Lancet* 2011; **377**: 242–250.
18. Coussens AK, Wilkinson RJ, Hanifa Y *et al.* Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. *Proc Natl Acad Sci U S A* 2012; **109**: 15449–15454.
19. Daley P, Jagannathan V, John KR *et al.* Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2015; **15**: 528–534.
20. Ralph AP, Waramori G, Pontororing GJ *et al.* L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. *PLoS One* 2013; **8**: e70032.
21. Salahuddin N, Ali F, Hasan Z *et al.* Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'. *BMC Infect Dis* 2013; **13**: 22.
22. Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. *Cochrane Database Syst Rev* 2011; CD006086.

## 8 Management of relapse, treatment failure and drug-resistant TB including directly observed therapy (DOT)

---

### 8.1 Management of treatment failure and relapse

---

- We recommend a microbiological diagnosis is pursued in all individuals with treatment failure and relapse, and that advice is sought from a centre with expertise in the management of such cases. (GPP)
- We recommend that individuals who are diagnosed with treatment failure/relapse are managed in conjunction with centres of expertise and receive, as per WHO recommendations [1] at least two to three new drugs from different classes while awaiting the results of drug susceptibility tests. (GPP)

### 8.2 Rationale

---

#### 8.2.1 Definitions

- Treatment failure: smear or culture positivity at month 5 or later [1].
- Relapse: individuals previously treated for TB, declared cured or treatment completed/at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by reinfection).
- Treatment after failure: individuals previously treated for TB and whose treatment failed at the end of their most recent course of treatment.

After 3 months of multidrug therapy for pulmonary TB caused by drug-susceptible organisms, up to 98% of individuals will have negative cultures and show clinical improvement. All individuals with positive cultures after 3 months of appropriate treatment must be evaluated carefully to identify the cause of the delayed conversion.

The main reason for treatment failure and relapse is suboptimal adherence to appropriate TB treatment regimens. Other factors that may increase the risk of treatment failure and relapse include presence or development of drug resistance or drug intolerance, use of intermittent TB therapy, malabsorption of TB drugs, extreme biological variation in the response to TB therapy and hetero-resistance or reinfection with drug-resistant strains. Antiretroviral therapy reduces the risk of treatment failure with acquired rifamycin resistance in HIV-positive individuals, perhaps related to prompt diagnosis of HIV, and earlier ART initiation preserving immune function [2].

If treatment failure is diagnosed, barriers to adherence should be carefully explored. Every effort should be made to establish a microbiological diagnosis. *M. tuberculosis* isolates should be sent for drug susceptibility testing and a rapid molecular rifampicin resistance test should be performed to exclude acquired rifampicin resistance.

One of the fundamental principles in managing individuals with treatment failure is never to add a single drug to a failing regimen, as this may lead to acquired resistance to the new drug. We recommend seeking expert help.

If relapse is diagnosed, a similar approach as described for treatment failure should be adopted. Individuals should be re-treated with an empirical regimen based on: prior drug susceptibility test results; prior TB treatment regimen; results of the rapid molecular rifampicin resistance test; and severity of disease. Empirical regimens usually comprise standard rifamycin-based TB therapy with the addition of other agents such as fluoroquinolone and an injectable agent such as amikacin. Once drug susceptibility test results are available, the regimen should be adjusted accordingly.

## 8.3 Management of drug-resistant TB

- We recommend, in individuals who are found to be infected with isoniazid mono-resistant isolates, a regimen of rifampicin, ethambutol, moxifloxacin and pyrazinamide for 2 months followed by rifampicin and moxifloxacin for 4–7 months. (GRADE 1B)
- We recommend that all individuals with rifamycin- (including multidrug-) resistant TB are managed in conjunction with centres of expertise in the management of drug-resistant TB. (GPP)
- We recommend that all individuals with rifampicin-resistant or multidrug-resistant TB who are not already on ART, initiate ART as soon as they are stable and TB treatment is tolerated. (GRADE 1B)

### 8.3.1 Rationale

Isolated isoniazid (INH) resistance is present in approximately 7.1% of individuals with HIV/TB in the UK [3]. Although these individuals tend to respond generally well to standard TB therapy, such therapy may incur a risk of treatment failure or relapse if administered intermittently [2]. Moxifloxacin (administered weekly with rifapentine in the continuation phase) was as effective as standard INH-containing TB therapy in individuals with drug-susceptible isolates [4]. Thus, 6 months of standard TB therapy in which INH is replaced with moxifloxacin is likely to be effective treatment for INH-resistant disease but one meta-analysis suggests prolonging the course has better outcomes. If moxifloxacin is not suitable, other fluoroquinolones may be considered. If there is intolerance to pyrazinamide, then moxifloxacin, rifampicin and ethambutol can be given for 9–12 months. (GRADE 1D) NICE recommends more prolonged administration (9–12 months) of rifamycins in combination with ethambutol for individuals with isoniazid mono-resistance [5-7].

Rifamycin mono-resistance is uncommon (approximately 0.3% in the UK) [3]. Although individuals infected with isolates that are mono-resistant to rifampicin have a better prognosis than those with multidrug-resistant (MDR) TB, they are at risk of treatment failure and acquisition of further drug resistance, and should be managed as MDRTB cases [5].

Multidrug-resistant TB is defined by the presence of resistance to at least isoniazid and rifampicin. When additional resistance to fluoroquinolones and second-line injectables (i.e. amikacin or capreomycin or kanamycin) is present, isolates are referred to as extensively drug-resistant (XDR TB) (see Section 5).

Approximately 1.6% of individuals with TB in the UK are infected with MDR isolates [3]. Risk factors for MDRTB include originating from/residence/travel in areas where MDR TB is endemic (especially Russia and Eastern Europe), previous TB treatment, and homelessness or hostel accommodation.

The optimal management of MDRTB is currently being investigated in randomised controlled trials. Individuals with rifamycin (including multidrug) resistant TB should be managed in conjunction with centres of expertise in the management of drug-resistant TB.

MDR/XDR TB should be treated by enhanced case management, which may involve DOT/VOT throughout the whole treatment.

Treatment regimens should be based on:

- Susceptibility testing for isoniazid, rifamycins, fluoroquinolones, injectable agents and other drugs if available;
- Treatment history;
- Tolerability of drugs for MDRTB;
- Local surveillance data.

### 8.3.2 Treatment regimens (adapted from [8])

These regimens should be prescribed by centres with expertise in MDR/TB. They are here as information only for those centres that may have shared care of individuals with HIV/DRTB.

- In individuals with rifampicin-resistant or multidrug-resistant TB, we recommend a regimen with at least five effective TB medicines during the intensive phase, including pyrazinamide and four core second-line TB medicines – one chosen from group A, one from group B, and at least two from group C (see Table 8.1). (GRADE 2C)

If the minimum of effective TB medicines cannot be composed as above, an agent from group D2 and other agents from D3 may be added to bring the total to five.

- In individuals with rifampicin-resistant or multidrug-resistant TB, we recommend that the regimen be further strengthened with high-dose isoniazid if *inhA* but not *katG* mutations are present, and/or ethambutol. (GRADE 2C)

### 8.3.2 Duration of MDR/XDR treatment

Eight months of intensive phase, using five or more drugs, followed by 12 months of three drugs depending on response (see Table 8.1). For example, 8 months of Z, Km, Lfx, Pto and Cs, followed by 12 months of Lfx, Pto and Cs

In individuals with rifampicin-resistant or multidrug-resistant TB who have not been previously treated with second-line drugs and in whom resistance to fluoroquinolones, PZA and second-line injectable agents has been excluded or is considered highly unlikely, a shorter MDRTB regimen of 9–12 months may be used instead of a conventional regimen.

Results of a trial of pretomanid/linezolid/bedaquiline for 6–9 months also show promise as a short-course therapy [9].

Surgical resection has been used successfully in the management of selected cases of pulmonary MDR TB [10].

Antiretroviral therapy reduces mortality among HIV-positive individuals with MDR TB [11-14] and should be offered to all individuals as soon as they are clinically stable and tolerating their TB treatment (see Section 9 and Appendix 7).

**Table 8.1.** Drugs with activity against MDRTB (adapted from [15] and from www.tbdrugmonographs.co.uk)

	Daily dose for adults	Comment	
<b>Group A: Fluoroquinolones</b>			
Levofloxacin (Lfx)	15 mg/kg	Care with QT prolongation	
Moxifloxacin (Mfx)	15 mg/kg	Ciprofloxacin and ofloxacin not recommended due to likely ineffectiveness	
<b>Group B: Second-line injectable agents</b>			
Kanamycin (Km)	15 mg/kg	Duration of use limited by ototoxicity and nephrotoxicity; monitor amikacin levels	
Amikacin (Am)	15 mg/kg		
Capreomycin (Cm)	15 mg/kg		
<b>Group C: Other core second-line agents</b>			
Prothionamide (Pto)	15–20 mg/kg	Limited by GI toxicity; add pyridoxine	
Cycloserine/terizidone (Cs/Trd)	15 mg/kg	Limited by neurotoxicity; monitor levels; add pyridoxine	
Linezolid (Lzd)	300 or 600 mg/day	Use limited by haematological and neurotoxicity High rates of sputum culture conversion reported in small cohort with XDR TB	
Clofazimine (Cfz)	100 mg	Caution: skin toxicity and QT prolongation	
<b>Group D: Add-on agents</b>			
<b>D1</b>	Pyrazinamide (Z)	30 mg/kg	DST less reliable than for other drugs; include for entire duration of treatment for MDRTB
	Ethambutol (E)	15–25 mg/kg	DST less reliable; include for entire duration of treatment for MDRTB if DST suggests activity
	High-dose isoniazid (H <sup>b</sup> )		Add pyridoxine
<b>D2</b>	Bedaquiline (Bdq)	400 mg daily for 2 weeks then 200mg 3× weekly for 22 weeks	Both drugs cause QT prolongation Bdq has very long half-life (5.5 months); consider if no effective regimen can be composed due to resistance or tolerability Licensed for maximum 6 months
	Delamanid (Dlm)	200 mg	
<b>D3</b>	p-aminosalicylic acid (PAS)	150 mg	Limited by GI toxicity
	Imipenem-cilastatin (Ipm)	1 g twice daily if >50 kg and 15 mg/kg twice daily if <50 kg	Doses based on imipenem component
	Meropenem (Mpm)	3 g	Carbopenems and clavulanate to be used together
	Amoxicillin-clavulanate (Amx-Clv)	875/125 mg every 12 hours	

### 8.3.4 Newer Drugs

#### 8.3.4.1 Bedaquiline (Bdq)

Bdq is used in the treatment of rifamycin-resistant TB. It has a novel mechanism of action. The drug inhibits mycobacterial adenosine triphosphate (ATP) synthase. It is an effective agent but may result in QTc prolongation

and should not be given to individuals with a QTc interval greater than 500 ms, history of torsade de pointes or cardiac ventricular arrhythmias, or severe coronary artery disease. It can cause hepatotoxicity and liver function should be monitored monthly. It has a very long half-life (months) and interacts with drugs that are inducers or inhibitors of cytochrome P450 3A4, and thus may result in potentially significant drug interactions (see Appendix 6).

WHO recommends that Bdq may be added to a drug regimen in adult individuals with pulmonary rifamycin-resistant TB. It should be used with caution with other drugs that cause QTc prolongation such as quinolones, and Cfz, both during and in the 6 months after stopping Bdq.

Bdq is given for 24 weeks, although case reports support more prolonged use [16].

#### 8.3.4.2 Delamanid (Dlm)

Dlm is a nitro-dihydro-imidazo-oxazole derivative, inhibiting a novel target in *Mycobacterium tuberculosis* cell wall mycolic acid synthesis. It is generally well tolerated. Other than QTc prolongation, adverse events observed in clinical studies with Dlm were generally mild to moderate. Individuals with a QTc interval greater than 500 ms should not receive the drug. There is a paucity of evidence for using Bdq and Dlm together.

## 8.4 Directly observed therapy (DOT)

---

- We recommend individualised, enhanced patient-centred care plans for all patients, some of these may include DOT and VOT. (GPP)
- We recommend against the routine use of DOT and VOT. (GRADE 1A)

### 8.4.1 Rationale

Directly observed therapy (DOT) is a supervision intervention, which requires that individuals be observed to swallow each dose of medication. The idea behind DOT is that it helps individuals to take their drugs as prescribed and to complete treatment, thus achieving cure and preventing the development of drug resistance. Evidence from randomised controlled trials and observational studies (of predominantly HIV-negative persons with drug-susceptible TB) suggests that DOT is not significantly better than self-administered therapy in preventing microbiological failure, relapse, or acquired drug resistance (ADR) [17,18]. Nonetheless, there are selected patient groups who may benefit from intensive support including DOT, such as migrants, prisoners, drug users, street- or sheltered-dwelling homeless, and those with mental health disorders [5,19]. A risk assessment should be made for each patient, as per NICE guidelines [5].

DRTB requires prolonged use of complex regimens with high pill burden and substantial toxicity. Consequently, individualised patient-centred care should be at the core of DRTB treatment/care plans and should always include measures to facilitate adherence. This may include DOT/VOT/supervised therapy, use of dosing devices, or treatment incentives; DOT may be undertaken at a health facility, in the workplace, in the community or at home.

Multidisciplinary (MDT) HIV and TB services should identify and address any factors that may make individuals interrupt or stop treatment [5]. Use of appropriate, suitably trained family or friends, social support and healthcare may promote adherence. Electronic DOT (eDOT or VOT) involves the use of electronic devices to document ingestion of medication at the appropriate date and time and can be an alternative to face-to-face contacts. Voice over internet protocol (VOIP, e.g. Skype) is becoming a more common method of performing eDOT or VOT, which may be particularly beneficial in instances where geographical distance is a factor.

## 8.5 References

---

1. World Health Organization. *WHO treatment guidelines for drug-resistant tuberculosis. 2016 update*. Geneva: 2016. Available at: <http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en> (accessed November 2017).

2. Narendran G, Menon PA, Venkatesan P *et al.* Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. *Clin Infect Dis* 2014; **59**: 1798–1804.
3. Public Health England. *Tuberculosis in the UK. 2014 report.* Available at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/360335/TB\\_Annual\\_report\\_4\\_0\\_300914.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360335/TB_Annual_report_4_0_300914.pdf) (accessed December 2017).
4. Jindani A, Harrison TS, Nunn AJ *et al.* High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. *N Engl J Med* 2014; **371**: 1599–1608.
5. NICE. *Tuberculosis. NICE guideline [NG33].* 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).
6. Stagg HR, Harris RJ, Hatherell HA *et al.* What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. *Thorax* 2016; **71**: 940–949.
7. Gegia M, Winters N, Benedetti A *et al.* Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 223–234.
8. World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. 2016.
9. Conradie F, Diacon AH, Everitt D *et al.* The NIX-TB trial of pretomanid, bedaquiline and linezolid to treat XDR-TB. *Conference on Retroviruses and Opportunistic Infections.* Seattle, WA, USA.
10. Fox GJ, Mitnick CD, Benedetti A *et al.* Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis. *Clin Infect Dis* 2016; **62**: 887–895.
11. Daniels JF, Khogali M, Mohr E *et al.* Time to ART initiation among patients treated for rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and treatment success. *PLoS One* 2015; **10**: e0142873.
12. Padayatchi N, Abdool Karim SS, Naidoo K *et al.* Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. *Int J Tuberc Lung Dis* 2014; **18**: 147–154.
13. Palacios E, Franke M, Munoz M *et al.* HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era. *Int J Tuberc Lung Dis* 2012; **16**: 348–354.
14. Gandhi NR, Andrews JR, Brust JC *et al.* Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. *Int J Tuberc Lung Dis* 2012; **16**: 90–97.
15. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. *Lancet Infect Dis* 2010; **10**: 621–629.
16. Lewis JM, Hine P, Walker J *et al.* First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. *Eur Respir J* 2016; **47**: 1581–1584.
17. Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. *Clin Infect Dis* 2013; **57**: 21–31.
18. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. *Cochrane Database Syst Rev* 2015; **5**: CD003343.
19. World Health Organization. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millenium Development Goals 2006.

## 9 When to start ART

---

### 9.1 Choice of antiretroviral treatment in individuals not on ART: when and what to start

---

- We recommend all individuals with TB should start ART as soon as is practicable and within 8–12 weeks of the TB diagnosis. (GRADE 1A)
- We recommend individuals with CD4 cell count  $<50$  cells/mm<sup>3</sup> start ART as soon as is practicable and within 2 weeks. (GRADE 1A)
- We recommend against the early initiation ( $<2$  months) of ART in individuals with CNS TB. (GRADE 1A)

#### 9.1.2 Rationale

ART is recommended for all individuals with HIV infection [1-3]. There is accumulating evidence from multiple RCTs in varied healthcare settings that early institution of ART in individuals with tuberculosis has mortality and morbidity benefits [4-10]. The timing of ART in individuals with TB depends on the level of immunodeficiency even though there may be a greater risk of IRIS [5-7,11] (see Section 12), high pill burden and the limited time for individuals to accept life-long ART.

It is only in individuals with CD4+ count  $<50$  cells/mm<sup>3</sup> that trials have consistently shown clinical benefit of starting ART within 2 weeks of commencing TB therapy as opposed to deferring ART for up to 2 months. Hence, we recommend that TB individuals with CD4+ counts  $<50$  cells/mm<sup>3</sup> start ART within 2 weeks as soon as they are stable and TB treatment is tolerated.

For individuals with CD4+ counts 50–200 cells/mm<sup>3</sup>, the clinical benefit of early ART (2–4 weeks vs. 8–12 weeks) is less clear. Trial data suggest it would appear safe to defer ART in TB individuals with CD4+ counts  $>50$  cells/mm<sup>3</sup> until the end of the induction phase (2 months), although ART may be discussed during this time and offered to those who are ready to start (see Appendix 9).

### 9.2 What ART to start in TB/HIV co-infection

---

- We recommend efavirenz (EFV) (standard dose) in combination with tenofovir (TDF) and emtricitabine (FTC) as first-line ART. (GRADE 1B)
- We suggest that raltegravir (RAL) can be used for individuals in whom EFV is contraindicated. (GRADE 2B)
- We recommend that rifabutin is used instead of rifampicin where effective ART necessitates the use of ritonavir-boosted protease inhibitors. (GRADE 1C)
- We recommend against the use of fixed-dose combinations containing TAF, when co-administered with rifampicin/rifabutin. (GRADE 1D)
- We recommend against the use of nevirapine (NVP) in ART-naïve individuals with TB treated with rifampicin. (GRADE1B)

#### 9.2.1 Rationale

EFV is the most widely studied ‘third agent’ in individuals with HIV/TB [5-8]. In clinical trials, EFV was co-administered with rifampicin at standard dose (600 mg once daily), together with zidovudine (ZDV) plus lamivudine (3TC) [8], didanosine (DDI) plus 3TC [5], stavudine (D4T) plus 3TC [6], or tenofovir plus emtricitabine (TDF/FTC) [7]. In cohort studies, EFV-based ART performed as well in HIV/TB co-infected individuals (all of whom received rifampicin) as in HIV-positive individuals without TB [12]. Hence, EFV plus TDF/FTC is considered the preferred regimen. Abacavir (ABC) may be best avoided even in those who are HLA negative unless renal insufficiency is present. IRIS and drug hypersensitivity are relatively common in HIV/TB co-infected individuals and potentially difficult to differentiate from ABC hypersensitivity (see Section 12).

Randomised controlled clinical trials have directly compared EFV versus raltegravir (RAL) or nevirapine (NVP) in HIV/TB patients.

In the Reflate TB, a Phase 2 trial, 155 subjects on rifampicin-containing TB therapy were randomly allocated to EFV 600mg, RAL 400mg bid, or RAL 800mg bid, each co-administered with TDF plus 3TC [13]. At 48 weeks, proportions of virologically suppressed patients were numerically higher in the RAL arm (76–78% vs. 63% in the EFV arm). Standard-dose RAL appeared to perform as well as double-dose RAL. Rates of virological failure (24–27%) and emergence of resistance (8–12%) were similar across the three study arms [13].

Similar outcomes have been reported when EFV and NVP were directly compared [14–16], although non-inferiority of NVP was not demonstrated in one trial [15] and inferior results were reported in another trial [17]. Cohort data suggest that NVP did not perform as well as EFV in individuals with treated with rifampicin-based TB therapy [12].

Due to significant drug–drug interactions, rilpivirine (RPV) should not be co-administered with rifampicin or rifabutin, and ritonavir (/r, RTV) and cobicistat (/c, COBI)-boosted protease inhibitors should not be used with rifampicin (see Section 10).

Cohort data have reported acceptable outcomes in individuals with TB who received ritonavir-boosted protease inhibitors with rifabutin [18] but there are few data with COBI. For dolutegravir (DTG), pharmacokinetic studies suggest that doubling the dose overcomes the rifampicin-induced enhanced metabolism of this agent [19]. However, no firm recommendation can be made regarding its use in TB co-infection pending the results of an ongoing randomised controlled clinical trial comparing DTG 50 mg bd with EFV 600 mg od in individuals with HIV and TB [20]. The use of tenofovir alafenamide (TAF) is not recommended in individuals who receive rifamycin-based TB therapy until data from an ongoing pharmacokinetic study become available (induction of P-glycoprotein by rifamycins may reduce TAF exposure).

### 9.3 Choice of antiretroviral treatment in individuals on established ART

---

- We recommend that individuals who develop TB on ART with undetectable HIV viral loads do not interrupt their ART. (GRADE 1A)
- We recommend that rifampicin-based TB treatment is used in individuals whose established ART consists of EFV (GRADE 1B), NVP (GRADE 2C), or RAL (GRADE 2C) plus two NRTIs.
- We recommend that rifabutin is used instead of rifampicin where established ART necessitates use of ritonavir. (GRADE 1C)

#### 9.3.1 Rationale

HIV-positive individuals should not interrupt fully suppressive ART [21]. Rifampicin-based TB therapy can be co-administered with EFV, NVP and RAL, and individuals on these agents may continue their current ART [12,13]. If effective ART necessitates the use of RTV-boosted protease inhibitors, rifabutin-based TB therapy should be used [18]. In the absence of COBI/rifabutin interaction data we prefer individuals are switched to RTV.

Individuals who develop TB on failing ART regimens typically have adherence problems and these will be severely compounded by the addition of multidrug TB therapy. We suggest that ART is interrupted in such individuals to allow the administration of rifampicin-based TB treatment for (at least) the full 2-month induction phase. This may be best done under directly observed conditions. (See Section 8).

### 9.4 References

---

1. Insight Start Study Group, Lundgren JD, Babiker AG *et al.* Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* 2015; **373**: 795–807.
2. Temprano ANRS Study Group, Danel C, Moh R *et al.* A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* 2015; **373**: 808–822.

3. Cohen MS, Chen YQ, McCauley M *et al.* Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; **365**: 493–505.
4. Abdool Karim SS, Naidoo K, Grobler A *et al.* Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med* 2010; **362**: 697–706.
5. Abdool Karim SS, Naidoo K, Grobler A *et al.* Integration of antiretroviral therapy with tuberculosis treatment. *N Engl J Med* 2011; **365**: 1492–1501.
6. Blanc FX, Sok T, Laureillard D *et al.* Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med* 2011; **365**: 1471–1481.
7. Havlir DV, Kendall MA, Ive P *et al.* Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med* 2011; **365**: 1482–1491.
8. Mfinanga SG, Kirenga BJ, Chanda DM *et al.* Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. *Lancet Infect Dis* 2014; **14**: 563–571.
9. Nanteza MW, Mayanja-Kizza H, Charlebois E *et al.* A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4(+) T-cell counts of  $\geq 350$  cells/ $\mu$ L. *J Infect Dis* 2011; **204**: 884–892.
10. Dean GL, Edwards SG, Ives NJ *et al.* Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. *AIDS* 2002; **16**: 75–83.
11. Naidoo K, Yende-Zuma N, Padayatchi N *et al.* The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. *Ann Intern Med* 2012; **157**: 313–324.
12. Boulle A, Van Cutsem G, Cohen K *et al.* Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. *JAMA* 2008; **300**: 530–539.
13. Grinsztejn B, De Castro N, Arnold V *et al.* Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Replate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. *Lancet Infect Dis* 2014; **14**: 459–467.
14. Sinha S, Raghunandan P, Chandrashekhar R *et al.* Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and tuberculosis infections in India: a pilot study. *BMC Infect Dis* 2013; **13**: 482.
15. Bonnet M, Bhatt N, Baudin E *et al.* Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. *Lancet Infect Dis* 2013; **13**: 303–312.
16. Manosuthi W, Sungkanuparph S, Tantanathip P *et al.* A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. *Clin Infect Dis* 2009; **48**: 1752–1759.
17. Swaminathan S, Padmapriyadarsini C, Venkatesan P *et al.* Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. *Clin Infect Dis* 2011; **53**: 716–724.
18. Rawson TM, Brima N, Almajid F *et al.* Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy. *J Acquir Immune Defic Syndr* 2015; **68**: e84–87.

19. Dooley KE, Sayre P, Borland J *et al.* Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. *J Acquir Immune Defic Syndr* 2013; **62**: 21–27.
20. ClinicalTrials.gov. Open-label study of dolutegravir (DTG) or efavirenz (EFV) for human immunodeficiency virus (HIV) - tuberculosis (TB) co-infection. 2017. Available at: <https://clinicaltrials.gov/ct2/show/NCT02178592> (accessed March 2017).
21. Strategies for Management of Antiretroviral Therapy Study Group, El-Sadr WM, Lundgren J *et al.* CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006; **355**: 2283–2296.

Consultation draft

# 10 Drug–drug interactions

---

## 10.1 ART/TB drug interactions and TDM use and interpretation (including MDR and XDR)

---

- We recommend undertaking a complete medicines reconciliation prior to starting treatment for either TB or HIV. (GPP)
- We recommend using prescribing resources (e.g. the Liverpool University HIV drug interactions website: [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org); or the Toronto General Hospital website: [www.hivclinic.ca/drug-information/drug-interaction-tables/](http://www.hivclinic.ca/drug-information/drug-interaction-tables/)) to screen for DDIs in all individuals with TB/HIV co-infection. (GPP)

The management and avoidance, where possible, of drug–drug interactions (DDI) between antiretrovirals and anti-TB drugs are central to good care, although this can be therapeutically challenging. Rifampicin is a potent inducer of cytochrome P450 enzymes and the drug transporter P-gp, and induction of these proteins in the gut and liver reduces bioavailability, and increases systemic clearance of a broad range of co-medications. Rifampicin also increases clearance of drugs through induction of glucuronidation. HIV NNRTIs (efavirenz, nevirapine, etravirine) are also P450 inducers whereas protease inhibitors and cobicistat are potent inhibitors of P450 CYP3A; ritonavir also being an inducer of glucuronidation.

## 10.2 DDIs between TB and HIV drugs

---

DDIs between ART and anti-tuberculosis drugs pose a particular challenge, especially if resistance to first-line regimens is likely for either infection (see Table 10.1). Discussion of DDIs between antiretrovirals and treatment for drug-resistant (MDR and XDR) TB is beyond the scope of these guidelines, and such individuals are best managed within specialised regional units: DDIs involving second-line TB agents and antiretrovirals can be seen in Table 10.2 or searched online at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) or [www.hivclinic.ca/drug-information/drug-interaction-tables/](http://www.hivclinic.ca/drug-information/drug-interaction-tables/).

Table 10.1 summarises key DDIs involving HIV and first-line TB agents, with a summary of how these DDIs should be managed. Particular note should be taken of the following:

- Efavirenz (EFV): standard doses are now recommended regardless of ethnicity or body weight. Previously, concerns about the potential reduction of EFV exposure by rifampicin led to weight-based dosing recommendations for EFV. However, standard doses of EFV in individuals also receiving rifampicin did not appear to be associated with high rates of virological failure (no direct dose comparison has been undertaken in this setting) [1]. Moreover, EFV exposures in HIV-infected patients, although variable, are not substantially lower on rifampicin therapy compared to concentrations off therapy when studied in populations, who have generally exhibited a high carriage of cytochrome CYP2B6 poor metaboliser genotype (516 G>T allele) [2-7]. In view of these data, we now recommend that standard doses of EFV should be prescribed with rifampicin. Therapeutic drug monitoring (TDM) of plasma EFV concentrations is not routinely recommended; however, in individuals with a high body mass index, or where virological responses appear blunted, TDM should be considered. In the absence of efficacy data, individuals maintained on EFV 400 mg once daily (following the results of the ENCORE clinical trial [8]) should increase to EFV 600 mg once daily while treated with rifampicin.
- The DDI between rifampicin and cobicistat (COBI) has not been studied, although the reduction of COBI exposure is likely to be major, and the combination is therefore contraindicated. By comparison, the impact on ritonavir (RTV) is modest (exposure reduced by 35%), and alternative strategies based on increasing doses of RTV and/or the boosted PI are being assessed. Nonetheless, switching to an alternative antiviral (e.g. raltegravir or dolutegravir) or rifabutin is preferred, where possible.
- Co-administration of COBI with rifabutin decreased COBI  $C_{trough}$  by 66%, did not change rifabutin exposure significantly, but increased 25 OH desacetyl rifabutin more than five-fold. As a result, 150 mg three times

per week dosing of rifabutin is recommended in the COBI product label. However, it should be noted that no clinical data are available on the efficacy of this dose, and 150 mg three times per week of rifabutin given with lopinavir/ritonavir (LPV/r) did not yield adequate rifabutin exposure [9]. Consequently, we advise caution when using rifabutin with COBI, and monitoring for rifabutin toxicity and HIV treatment response.

- Rifampicin reduces raltegravir (RAL) exposure by 40%. The REFLATE Study [10] reported that dose increase of RAL to 800 mg bd was well tolerated but over-compensated for this interaction, whereas standard dosing (400 mg bd) only resulted in small decreases in RAL exposure. However, given the wide variability in  $C_{trough}$  at standard doses (with some individuals falling below target), and in the absence of adequately powered studies confirming the efficacy of standard dosing, we suggest using 800 mg bd of RAL with rifampicin.
- Rifampicin is likely to exert different effects on tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF). Both TDF and TAF are substrates for P-gp; however, TDF is present in the systemic circulation as tenofovir (which is not a P-gp substrate) whereas TAF is converted to tenofovir largely within cells. Rifampicin as a potent inducer of P-gp is anticipated to have a significant effect on the bioavailability of TAF. By contrast, the impact of rifampicin on tenofovir is not likely to be clinically significant [11]. Fixed-dose combinations containing either TDF or TAF that also contain COBI are contraindicated with rifampicin (see above).

We do not recommend use of nevirapine (NVP) in HIV-naïve individuals with either rifampicin or rifabutin. However, if the patient is stable on NVP it can be continued. Caution is advised when rifabutin is used with NVP since rifabutin exposures are increased by 17%, and toxicity may be increased (Table 10.3).

It should be noted that recommendations for managing DDIs may sometimes differ between the FDA and EMEA: for example, rilpivirine (RPV) is contraindicated with rifabutin in the US, whereas increased doses of RPV are recommended by the EMEA. We have sought to highlight any significant differences and provide guidance on how these interactions can be managed in clinical practice.

**Table 10.3.** Drug interactions between rifabutin and ART

ART	Dose	TB therapy	Dose
Boosted PI	No change	RBT	Varies 150 or 300 mg od or 3/7
NVP	200 mg bd	RBT	300 mg od
EFV	600 mg od	RBT	450 mg od
RAL	400 mg bd	RBT	300 mg od
EVG/c	No change	RBT	150 mg 3/7
DTG	50mg od	RBT	300 mg od

### 10.2.1 Other DDIs

Individuals with TB/HIV co-infection often have multiple co-morbidities such as diabetes, chronic obstructive pulmonary disease (COPD), chronic hepatitis and cardiovascular disease. Rifampicin (and also HIV drugs such as NNRTIs, RTV and COBI) is also likely to impact on the safety or efficacy of these treatments. It is not possible to provide a complete list of DDIs, and prescribers should consult their usual prescribing resources when attempting to manage these interactions. For DDIs involving HIV drugs, the Liverpool ([www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)) or Toronto websites ([www.hivclinic.ca/drug-information/drug-interaction-tables/](http://www.hivclinic.ca/drug-information/drug-interaction-tables/)) are recommended.

Some common challenges are listed:

- Metabolism of corticosteroids (e.g. prednisolone) is accelerated by rifamycins and higher doses are needed.
- The dose of steroid should be increased by around 50% with rifampicin and 33% with rifabutin.
- Interactions are also likely with cardiovascular, antidepressant, antiepileptic and immunosuppressant drugs. Where there may be opposing effects, any induction effect from rifampicin is likely to predominate.

- Concomitant chronic viral hepatitis infection increases the risk of liver toxicity with HIV and TB therapy; however, this does not preclude the use of first-line agents for either infection. Use of directly acting antivirals for hepatitis C is contraindicated or not recommended with rifampicin, and DDIs involving HCV drugs and anti-tuberculosis therapy can be searched at [www.hep-druginteractions.org](http://www.hep-druginteractions.org). We suggest for the vast majority of individuals to treat TB first, then HCV.
- Diabetes mellitus triples the risk of active TB [12], and HIV-infection is also associated with increased prevalence of glucose intolerance. Rifampicin will lower exposures to sulfonylureas, and most other diabetic drugs (with the exception of insulin and metformin). This could significantly impair glycaemic control. Exposure to gliptins may also be modestly reduced by rifampicin. Isoniazid is an inhibitor of some cytochrome P450 isoforms, and inhibition of clearance of some sulfonylureas may occur. However, when co-dosed with rifampicin, the enzyme induction by rifampicin is likely to predominate.

### 10.2.2 Managing DDIs

Clinical surveys have consistently demonstrated poor medication recording, and incomplete concordance between hospital and community health records in HIV-infected patients.

- Particular co-medications known to be poorly captured must be actively sought, e.g. oral contraceptives, long-acting hormonal contraceptive implants, herbal medications and vitamins, ‘over-the-counter drugs’ and recreational drugs. Clinically significant DDIs are likely in TB-HIV co-infected patients.

### 10.2.3 Therapeutic drug monitoring (TDM)

The use of TDM of HIV or TB drugs in managing individuals with TB/HIV co-infection should only be considered in specific scenarios, such as:

- Concerns over treatment adherence (HIV or TB drugs)
- Blunted virological response, or development of low-level viraemia (HIV drugs)
- Individuals receiving rifabutin 150 mg three times per week with COBI (TB drug)

This list is not exhaustive, and TDM may sometimes help to distinguish the contribution of specific components (e.g. adherence, excluding a significant DDI, body weight) within complex clinical scenarios.

## 10.3 References

---

1. Boulle A, Van Cutsem G, Cohen K *et al*. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. *JAMA* 2008; **300**: 530–539.
2. Luetkemeyer AF, Rosenkranz SL, Lu D *et al*. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. *Clin Infect Dis* 2013; **57**: 586–593.
3. Mukonzo JK, Bisaso RK, Ogwal-Okeng J *et al*. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. *Pharmacogenomics* 2016; **17**: 603–613.
4. Habtewold A, Makonnen E, Amogne W *et al*. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. *Pharmacogenomics* 2015; **16**: 1047–1064.
5. Gengiah TN, Botha JH, Yende-Zuma N *et al*. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. *Antivir Ther* 2015; **20**: 297–306.
6. Bhatt NB, Baudin E, Meggi B *et al*. Nevirapine or efavirenz for tuberculosis and HIV coinfecting patients: exposure and virological failure relationship. *J Antimicrob Chemother* 2015; **70**: 225–232.

7. Bertrand J, Verstuyft C, Chou M *et al.* Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. *J Infect Dis* 2014; **209**: 399–408.
8. Encore Study Group, Puls R, Amin J *et al.* Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. *Lancet* 2014; **383**: 1474–1482.
9. Boulanger C, Hollender E, Farrell K *et al.* Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. *Clin Infect Dis* 2009; **49**: 1305–1311.
10. Grinsztejn B, De Castro N, Arnold V *et al.* Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Replate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. *Lancet Infect Dis* 2014; **14**: 459–467.
11. Droste JA, Verweij-van Wissen CP, Kearney BP *et al.* Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. *Antimicrob Agents Chemother* 2005; **49**: 680–684.
12. Riza AL, Pearson F, Ugarte-Gil C *et al.* Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. *Lancet Diabetes Endocrinol* 2014; **2**: 740–753.

**Table 10.1.** Drug interactions between anti-tuberculosis and antiretroviral drugs

	Eth	INH	PZA	Rbt	Rif	Notes
ATV	◆4	◆4	◆4	■	●1	<ul style="list-style-type: none"> <li>Unboosted ATV is contraindicated with Rif (ATV exposure ↓80%)</li> <li>If using Rbt, reduce Rbt dose to 150 mg daily; monitor for Rbt toxicity</li> </ul>
ATV/r	◆4	◆4	◆4	■1	●1	<ul style="list-style-type: none"> <li>Boosted ATV is contraindicated with Rif</li> <li>If using Rbt, reduce Rbt dose to 150 mg daily, or 300 mg 3×/w; monitor for Rbt toxicity</li> </ul>
ATV/c or DRV/c	◆4	◆4	◆4	■4	●4	<ul style="list-style-type: none"> <li>COBI is contraindicated with Rif; monitor for Rbt toxicity</li> </ul>
DRV/r	◆4	◆4	◆4	■3	●2	<ul style="list-style-type: none"> <li>Has not been studied with Rif – modelling and simulations suggest higher DRV/r doses could potentially overcome Rif induction but safety data are lacking and the combination is not recommended</li> <li>If using Rbt, reduce RBT dose to 150 mg daily, or 300 mg 3×/w; monitor for Rbt toxicity</li> </ul>
LPV/r	◆4	◆4	◆4	■1	●1	<ul style="list-style-type: none"> <li>Use of Rif not recommended. However, doubling the dose of LPV/r (e.g. 800/200 mg bd) or ‘super-boosting’ with RTV (e.g. 400/400 mg bd) has been used in adults, and additional RTV boosting in children. Monitor for liver and GI toxicity. Once-daily LPV/r is contraindicated with Rif</li> <li>If using Rbt, reduce Rbt dose to 150 mg daily. Dosage of Rbt 300 mg 3×/w with LPV/r has been associated with sub-therapeutic Rbt exposure, and development of rifamycin mono-resistance; monitor for Rbt toxicity</li> </ul>
EFV	◆4	◆3	◆4	■3	■1	<ul style="list-style-type: none"> <li>EFV can be prescribed at standard doses with Rif, regardless of ethnicity or weight. Weight-based dose increment of EFV is no longer recommended with Rif. However, reduced doses of EFV 400 mg daily is not recommended</li> <li>If using Rbt, increase Rbt dose to 450 mg daily to compensate for reduced exposure due to EFV; monitor for Rbt toxicity</li> </ul>
ETR	◆4	◆4	◆4	■2	●2	<ul style="list-style-type: none"> <li>Use of Rif should be avoided. A case report observed reduced ETR exposures but successful virological suppression with ETR 200 mg bd and Rif</li> <li>ETR can be administered at standard doses (in the absence of a second enzyme inducer) with Rbt. ETR exposure ↓ 37% – monitor virological response</li> </ul>
NVP	◆4	◆4	◆4	■3	●1	<ul style="list-style-type: none"> <li>Use of Rif is not recommended (label states contraindicated). NVP levels ↓ 20–55%, and the CARINEMO Study failed to demonstrate non-inferiority against EFV. If starting NVP on a patient established on Rif, do not use lead-in dosing</li> <li>Rbt should be used with caution in individuals on NVP. In contrast to EFV, NVP increased Rbt exposure by 17%; standard doses of both drugs should be administered</li> </ul>
RPV	◆4	◆4	◆4	●3	●1	<ul style="list-style-type: none"> <li>RPV is contraindicated with Rif</li> <li>Rbt decreased RPV exposure by 46%, and the combination is not recommended (contraindicated in US PI).</li> </ul>

						Increased doses of RPV 50mg od should be used (European SPC)
ABC	◆4	◆4	◆4	◆4	■4	<ul style="list-style-type: none"> <li>Potential mild decrease in ABC exposure due to increased glucuronidation with Rif, use standard doses of both drugs</li> </ul>
FTC	◆4	◆4	◆4	◆4	◆4	<ul style="list-style-type: none"> <li>No significant drug interactions anticipated</li> </ul>
3TC	◆4	◆4	◆4	◆4	◆2	<ul style="list-style-type: none"> <li>No significant drug interactions anticipated</li> </ul>
TDF	◆4	◆4	◆4	◆4	◆3	<ul style="list-style-type: none"> <li>No clinically significant interaction with Rif (tenofovir exposure reduced 12%)</li> <li>No clinically significant interaction with Rbt (<b>not studied</b>)</li> </ul>
TAF	◆4	◆4	◆4	■4	■4	<ul style="list-style-type: none"> <li>Rif may reduce TAF bioavailability through transporter (P-gp) induction and is not recommended. (Note: TAF or TDF administered with COBI is contraindicated because of Rif induction of COBI metabolism)</li> <li>Rbt expected to reduce TAF exposure through P-gp induction, the combination is not recommended</li> </ul>
ZDV	◆4	◆4	◆4	◆2	■2	<ul style="list-style-type: none"> <li>Rif increases clearance of ZDV, reducing plasma exposure by 47%. Use with caution ('Avoid' European SPC; 'dose modification not warranted' US PI)</li> </ul>
DTG	◆4	◆4	◆4	◆2	■1	<ul style="list-style-type: none"> <li>Rif decreased DTG exposures by 54%, increasing dose to DTG 50 mg bd has been used in limited clinical studies and is recommended</li> <li>Rbt has no clinically significant effect on DTG. Use standard doses of both drugs</li> </ul>
EVG/c	◆4	◆4	◆4	■3	●2	<ul style="list-style-type: none"> <li>COBI is contraindicated with Rif</li> <li>Caution with Rbt. EVG C<sub>trough</sub> ↓ 67%. If using Rbt, reduce Rbt dose to 150 mg daily; monitor for Rbt toxicity and HIV treatment response</li> </ul>
RAL	◆4	◆4	◆4	◆2	■1	<ul style="list-style-type: none"> <li>Rif reduces RAL exposure by 40%. The REFLATE Study reported that dose increase of RAL to 800 mg bd was well tolerated but over-compensated for this interaction, whereas standard dosing (400 mg bd) only resulted in small decreases in RAL exposure. However, given the wide variability in C<sub>trough</sub> at standard doses (with some individuals falling below target), and in the absence of adequately powered studies confirming the efficacy of standard dosing, we prefer using 800 mg bd of RAL with Rif</li> <li>No clinically significant interaction was observed between RAL and Rbt; use standard doses of both drugs</li> </ul>

MVC	◆4	◆4	◆4	■4	■1	<ul style="list-style-type: none"> <li>Rif reduces MVC exposure by 60–70% (note: MVC was dosed at 100 mg bd in this study, and the magnitude of drug interaction with full dose MVC is unknown). MVC should be dosed at 600 mg bd with Rif. MVC should be avoided with Rif in individuals also taking another enzyme inducer (e.g. EFV, NVP or ETR), or in those with an eGFR &lt;30mL/min or on haemodialysis</li> <li>No clinically significant interaction was observed between MVC and Rbt; use standard doses of both drugs. (Note: MVC and Rbt doses should be reduced in the presence of a protease inhibitor or COBI)</li> </ul>
T20	◆4	◆4	◆4	◆4	◆4	<ul style="list-style-type: none"> <li>No significant drug interactions anticipated</li> </ul>

Consultation draft

**Table 10.2.** Drug interactions between second-line anti-tuberculosis and antiretroviral drugs

	Group A		Group B			Group C				Group D*					
	Levo	Moxi	Amik	Capr	Kan	Pro	Cyclo/T eri	Linez	Clof	Bedaq	Del	PAS	Imi/Cil	Mero	Co-amox
ATV	■ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	■ 4	■ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4
ATV/r	■ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	■ 4	■ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4
ATV/c or DRV/c	■ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	■ 4	■ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4
DRV/r	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4
LPV/r	■ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	■ 4	■ 4	■ 2	◆ 4	◆ 4	◆ 4	◆ 4
	■	■				■	■	■	■	■	■	■	■	■	■
EFV	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 2	◆ 3	◆ 4	◆ 4	◆ 4	◆ 4
ETR	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	■ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4
NVP	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4

	Group A		Group B			Group C				Group D*						
						4										
RPV	■	■	◆	◆	◆	■	◆	◆	■	■	■	■	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	■	■				■	■	■	■	■	■	■	■	■	■	■
ABC	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
FTC	◆	◆	■	■	■	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
3TC	■	◆	■	■	■	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TDF	◆	◆	■	■	■	◆	◆	◆	◆	◆	◆	■	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	2	4	4	4	4	4
TAF	◆	◆	■	■	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
ZDV	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
DTG	◆	◆	◆	■	◆	■	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
						4										
EVG/c	◆	◆	◆	◆	◆	■	◆	◆	◆	■	■	◆	◆	◆	◆	◆

	Group A		Group B			Group C				Group D*					
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
RAL	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4
MVC	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	■ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4
T20	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4	◆ 4

# 11 Drug absorption, toxicity and management

---

## 11.1 Malabsorption of drugs

---

In HIV infection, malabsorption has been reported with all first-line anti-tuberculosis drugs, as well as ethionamide and cycloserine. Absorption may be decreased in individuals with a low CD4+ cell count because of HIV enteropathy or other HIV-related gut disease. Sub-therapeutic plasma drug concentrations may cause treatment failure and drug resistance [1,2]. Although some studies show lower peak concentrations of rifampicin and ethambutol, as well as a lower AUC, compared with controls [3-7], there are other data suggesting that rifampicin is well absorbed in HIV-infected patients, including those with other AIDS conditions or diarrhoea [8]. There are few data showing a correlation of treatment failure with poor absorption [9]. Intravenous preparations of rifampicin, isoniazid and ethambutol are available for individuals without a reliable enteric route of administration, e.g. on ITU or post-operatively (see Table 11.2)

## 11.2 Overlapping toxicity profiles of antiretrovirals and TB therapy

---

Adverse reactions to drugs are common among individuals with HIV-related TB, especially if taking ART concomitantly. Rash, fever and hepatitis are common adverse effects of anti-tuberculosis drugs, especially rifampicin, isoniazid and pyrazinamide. NNRTIs and co-trimoxazole cause similar adverse reactions.

The co-administration of these drugs can lead to difficult clinical management decisions if these occur, especially if ART and TB drugs are started concurrently.

## 11.3 Drug induced liver injury (DILI)

---

Drug-induced liver injury has been defined as [10]:

- Serum AST or ALT >3× upper limit of normal in the presence of symptoms, or
- Serum AST or ALT >5× upper limit of normal in the absence of symptoms

Other causes of liver dysfunction, such as resulting from other administered drugs and viral hepatitis, should be investigated.

Hepatotoxicity may be caused by many drugs used in the treatment of HIV-positive patients, for instance azoles and macrolides, and not all hepatotoxic reactions are due to anti-tuberculosis therapy.

The risk of hepatotoxicity caused by isoniazid increases with age, occurring in <0.3% of those under 35 years old and in 2.3% of those >50 years old. It is also higher in those with heavy alcohol intake or hepatitis C virus co-infection and in those also on rifampicin. High rates of adverse reactions requiring changes in therapy have been reported in HIV-infected individuals who are likely to have some or all of the other risk factors mentioned above. In one study, adverse reactions were present in 26% of an HIV-infected cohort compared with 3% of an HIV-uninfected group and other studies have shown similar results [11,12].

Another study reported little increase in hepatotoxicity in HIV-positive individuals with TB although only 16.3% were receiving ART and the study included children [13].

### 11.3.1 Management of suspected DILI

- We recommend the following when serum AST or ALT >3× upper limit of normal in the presence of symptoms, or serum AST or ALT >5× upper limit of normal in the absence of symptoms (GRADE 1B):

- Consider stopping all potentially hepatotoxic drugs immediately, including isoniazid, rifampicin, pyrazinamide and co-trimoxazole. cART should only be stopped/modified if it is likely to be causing hepatotoxicity.
- Check serology for hepatitis A, B and C, and if clinically indicated delta and hepatitis E.
- Enquire about exposure to other hepatotoxins, including alcohol.
- As resolution of the hepatitis may be prolonged, until the cause of the hepatitis is identified, it may be necessary to treat with two or more anti-tuberculosis medications without significant risk of hepatotoxicity, such as ethambutol, streptomycin, amikacin/kanamycin, capreomycin or a fluoroquinolone (N.B. moxifloxacin can cause a severe although infrequent hepatitis). Monitor serum AST (or ALT), bilirubin and symptoms frequently.
- Once AST drops to less than twice the upper limit of normal and symptoms have significantly improved, first-line medications can be restarted using a re-introduction regimen (see Table 11.1). These recommendations are based on common practice and have not been formally validated in clinical trials. Data in HIV-negative/unknown individuals suggest that once the AST/ALT is <100 IU/L then full-dose treatment may be reintroduced [14]: whether this also applies to HIV co-infected individuals remains unclear.
- If the drugs cannot be restarted or the initial reaction was life-threatening then an alternative regimen should be used (see Section 11.4).

## 11.4 Pre-existing liver disease

---

All individuals should be screened for active hepatitis B and C. The risk of hepatotoxicity with pre-existing liver disease is greatest with pyrazinamide, then isoniazid, and then rifampicin. Isoniazid and rifampicin are essential drugs in short-course TB treatment regimens and should be used whenever possible, even in the presence of pre-existing liver disease.

In individuals with baseline abnormal hepatic transaminases, a rise of two-to-three times this abnormal baseline should be used as the threshold for hepatotoxicity [10].

If hepatotoxicity occurs, then other regimens can be used as follows:

- Avoid pyrazinamide and treat with isoniazid and rifampicin for 9 months, adding ethambutol for the first 8 weeks or until isoniazid and rifampicin susceptibility is demonstrated.
- Avoid isoniazid and treat with rifampicin, ethambutol and pyrazinamide for 2 months, followed by 10 months of rifampicin and ethambutol.
- Use only one potentially hepatotoxic agent in individuals with severe liver disease and treat with rifampicin plus ethambutol for 12–18 months, preferably with another agent such as a fluoroquinolone for the first 2 months.  
(There are no data to support this recommendation.)

In individuals with pre-existing liver disease, frequent clinical and laboratory monitoring should be performed to detect drug-induced hepatic injury. This should include AST (or ALT), platelet count and prothrombin time at least 2-weekly initially. Individuals should be told to immediately report symptoms such as anorexia, nausea, vomiting, abdominal pain or jaundice [15,16].

## 11.5 Gastrointestinal side effects

---

Epigastric pain, nausea and vomiting are common, especially in the first 2–3 weeks after starting anti-tuberculosis therapy. If the patient has no evidence of hepatic disease and is unresponsive to symptomatic treatment, for instance with anti-emetics, then they can:

- Take medications with meals (except with doses under 600 mg rifampicin daily): food delays or decreases the absorption of isoniazid and rifampicin but the effect is moderate and of little clinical significance;
- Change the time of dosing;

- Switch to a regimen that does not have food restrictions such as rifabutin, ethambutol, pyrazinamide and a fluoroquinolone.

Individuals should avoid dividing doses or changing to alternative drugs if at all possible, although dividing the dose, for instance of pyrazinamide, can improve tolerability.

See Table 11.2 for further guidance.

## 11.6 Peripheral neuropathy

---

Pyridoxine 10 mg daily should be used in all individuals receiving isoniazid.

If peripheral neuropathy occurs, the dose of pyridoxine can be increased to 50 mg od.

Second-line drugs, such as cycloserine and prothionamide, need higher-dose pyridoxine.

## 11.7 Rash

---

Rash is often mild/moderate and usually occurs in the first 2 months of treatment. Mild rash without mucosal involvement can be treated symptomatically. More widespread or worsening rash or individuals who also have systemic symptoms require cessation of all drugs, and on recovery careful drug re-introduction (see Table 11.1).

A confounding issue is that individuals may have also recently started co-trimoxazole or ART and so the offending drug can be difficult to identify.

There are several recommendations for drug reintroduction. Although they have been used in liver disease they can be used for rash GRADE 1–3.

## 11.8 Reintroduction of TB drugs after DILI or rash

---

For most mild/moderate reactions, once AST or ALT levels fall below twice the upper limit of normal, bilirubin levels return to the normal range and hepatotoxic symptoms have resolved then:

- Reintroduce all the drugs at once; or
- Sequentially reintroduce each of the anti-TB drugs at full dose over a period of no more than 10 days, starting with ethambutol and either isoniazid (with pyridoxine) or rifampicin.

If the reaction was moderate or there was a recurrence of the DILI or rash on reintroduction as above, then give ethambutol full dose and follow the protocol in Table 11.1.

If the reaction is severe or occurs again after the above reintroduction, start with one-tenth of the first-day dose for each drug.

Individuals who are infectious should be treated with at least two active drugs while standard therapy is reintroduced. Suitable agents would be ethambutol and streptomycin or ethambutol and moxifloxacin.

**Table 11.1.** Protocol for reintroducing TB drugs after DILI or rash GRADE 1–3 (adapted from a reintroduction protocol for cutaneous reactions [17]).

Day	Isoniazid (mg)	Rifampicin (mg)	Pyrazinamide (mg)
1	50		
2	150		
3	300		
4	300	75	
5	300	150	
6	300	300	
7	300	450 <50 kg or 600 >50 kg	
8	300	450/600	250
9	300	450/600	500
10	300	450/600	1000
11	300	450/600	1500 <50 kg or 2000 >50 kg
12	300	450/600	1500/2000
13	300	450/600	1500/2000

## 11.9 References

- Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. *N Engl J Med* 1995; **332**: 336–337.
- Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. *N Engl J Med* 1993; **329**: 1122–1123.
- Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. *N Engl J Med* 1992; **327**: 1817–1818.
- Peloquin CA, Nitta AT, Burman WJ *et al.* Low antituberculosis drug concentrations in patients with AIDS. *Ann Pharmacother* 1996; **30**: 919–925.
- Perlman DC, Segal Y, Rosenkranz S *et al.* The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. *Clin Infect Dis* 2005; **41**: 1638–1647.
- Sahai J, Gallicano K, Swick L *et al.* Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. *Ann Intern Med* 1997; **127**: 289–293.
- Tappero JW, Bradford WZ, Agerton TB *et al.* Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. *Clin Infect Dis* 2005; **41**: 461–469.
- Taylor B, Smith PJ. Does AIDS impair the absorption of antituberculosis agents? *Int J Tuberc Lung Dis* 1998; **2**: 670–675.
- Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. *Clin Infect Dis* 1999; **28**: 419–429; quiz 430.
- Saukkonen JJ, Cohn DL, Jasmer RM *et al.* An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med* 2006; **174**: 935–952.

11. Devoto FM, Gonzalez C, Iannantuono R *et al.* Risk factors for hepatotoxicity induced by antituberculosis drugs. *Acta Physiol Pharmacol Ther Latinoam* 1997; **47**: 197–202.
12. Yee D, Valiquette C, Pelletier M *et al.* Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. *Am J Respir Crit Care Med* 2003; **167**: 1472–1477.
13. Marks DJ, Dheda K, Dawson R *et al.* Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. *Int J STD AIDS* 2009; **20**: 339–345.
14. Sharma SK, Singla R, Sarda P *et al.* Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. *Clin Infect Dis* 2010; **50**: 833–839.
15. Sadaphal P, Astemborski J, Graham NM *et al.* Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with *Mycobacterium tuberculosis*. *Clin Infect Dis* 2001; **33**: 1687–1691.
16. Ungo JR, Jones D, Ashkin D *et al.* Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. *Am J Respir Crit Care Med* 1998; **157**: 1871–1876.
17. Girling DJ. Adverse effects of antituberculosis drugs. *Drugs* 1982; **23**: 56–74.

**Table 11.2.** Drug dosing modifications: food effect, alternatives in swallowing difficulties and doses in renal impairment

Drug	Food effect	Alternatives for individuals with swallowing difficulties	Considerations for renal impairment
Ethambutol 400 mg tablets 100 mg tablets	Absorption is not significantly impaired by food	Only film-coated tablets available: strength 400 mg or 100 mg	Ethambutol should preferably be avoided in individuals with renal impairment, but if used the dose should be reduced as determined by blood levels of ethambutol. Toxic effects are more common if renal function is impaired.  No specific recommendation for haemodialysis
Isoniazid Oral	See fixed dose combinations below	See fixed dose combinations below  Isoniazid is available as 50 mg/2 mL solution for injection (see below)	No dosage reduction of Isoniazid is necessary when given to individuals with mild renal failure  Use of isoniazid should be carefully monitored in individuals with severe renal impairment (glomerular filtration rate of less than 10 mL/minute) and slow acetylator status: a dose reduction of about 100 mg might be necessary to maintain trough plasma levels at less than 1 µg/mL  Isoniazid is removed by both haemodialysis and peritoneal dialysis; therefore, isoniazid should be administered immediately after dialysis
Isoniazid 50 mg/2 mL solution for injection (intramuscular, intravenous, intrapleural, or intrathecal injection)	Tyramine- and histamine-containing foods should be avoided by individuals receiving isoniazid	N/A	No dosage reduction of Isoniazid is necessary when given to individuals with mild renal failure  Use of isoniazid should be carefully monitored in individuals with severe renal impairment (glomerular filtration rate of less than 10 mL/minute) and slow acetylator status: a dose reduction of about 100 mg might be necessary to maintain trough plasma levels at less than 1 µg/mL  Isoniazid is removed by both haemodialysis and peritoneal dialysis; therefore, isoniazid should be administered immediately after dialysis
Pyrazinamide Zinamide® Tablets 500 mg	No specific recommendation	Only tablet formulation available	Reduction in the size and/or frequency of dose is recommended for individuals with renal insufficiency  No specific recommendation for haemodialysis
Rifabutin Mycobutin® 150 mg capsules	Dose can be taken at any time, independently of meals	Only capsule formulation available	Severe renal impairment (creatinine clearance below 30 mL/min) requires a dosage reduction of 50%  No specific recommendation for haemodialysis
Rifampicin	Dose should preferably	Rifadin® infusion	At a dose of up to 600 mg/day, half-life does not differ in individuals with renal failure and, consequently, no

Rifadin® 300 mg Capsules	be taken at least 30 minutes before a meal or 2 hours after a meal to ensure rapid and complete absorption	(see below) Rifadin® 100 mg/5 mL oral suspension (dose is equivalent to capsule formulation)	dosage adjustment is required Cautions should be taken in case of renal impairment if dose >600 mg/day No specific recommendation for haemodialysis																								
Rifampicin Rifadin® for Infusion 600 mg	N/A	N/A	At a dose of up to 600 mg/day, half-life does not differ in individuals with renal failure and consequently, no dosage adjustment is required Cautions should be taken in case of renal impairment if dose >600 mg/day No specific recommendation for haemodialysis																								
Streptomycin IM or IV injection/infusion	N/A	N/A	Streptomycin is excreted unchanged in the urine by glomerular filtration; dosage should also be reduced in those with renal impairment, and plasma-drug concentration should be monitored No specific recommendation for haemodialysis																								
Levofloxacin Tavanic® Evoxil® Film-coated tablets 5 mg/mL solution for infusion	Tablets may be taken during meals or between meals; should be taken at least 2 hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids	Tablet can be divided into equal halves at score line, but swallowed without crushing Solution for infusion	<table border="1"> <thead> <tr> <th></th> <th colspan="3">Dose regimen</th> </tr> <tr> <th></th> <th>250 mg/24 h</th> <th>500 mg/24 h</th> <th>500 mg/12 h</th> </tr> </thead> <tbody> <tr> <td><b>Creatinine clearance</b></td> <td><i>first dose: 250 mg</i></td> <td><i>first dose: 500 mg</i></td> <td><i>first dose: 500 mg</i></td> </tr> <tr> <td>50–20 mL/min</td> <td><i>then: 125 mg/24 h</i></td> <td><i>then: 250 mg/24 h</i></td> <td><i>then: 250 mg/12 h</i></td> </tr> <tr> <td>19–10 mL/min</td> <td><i>then: 125 mg/48 h</i></td> <td><i>then: 125 mg/24 h</i></td> <td><i>then: 125 mg/12 h</i></td> </tr> <tr> <td>&lt;10 mL/min (including haemodialysis and CAPD) <sup>1</sup></td> <td><i>then: 125 mg/48 h</i></td> <td><i>then: 125 mg/24 h</i></td> <td><i>then: 125 mg/24 h</i></td> </tr> </tbody> </table> <p><sup>1</sup>No additional doses required after haemodialysis or continuous ambulatory peritoneal dialysis</p>		Dose regimen				250 mg/24 h	500 mg/24 h	500 mg/12 h	<b>Creatinine clearance</b>	<i>first dose: 250 mg</i>	<i>first dose: 500 mg</i>	<i>first dose: 500 mg</i>	50–20 mL/min	<i>then: 125 mg/24 h</i>	<i>then: 250 mg/24 h</i>	<i>then: 250 mg/12 h</i>	19–10 mL/min	<i>then: 125 mg/48 h</i>	<i>then: 125 mg/24 h</i>	<i>then: 125 mg/12 h</i>	<10 mL/min (including haemodialysis and CAPD) <sup>1</sup>	<i>then: 125 mg/48 h</i>	<i>then: 125 mg/24 h</i>	<i>then: 125 mg/24 h</i>
	Dose regimen																										
	250 mg/24 h	500 mg/24 h	500 mg/12 h																								
<b>Creatinine clearance</b>	<i>first dose: 250 mg</i>	<i>first dose: 500 mg</i>	<i>first dose: 500 mg</i>																								
50–20 mL/min	<i>then: 125 mg/24 h</i>	<i>then: 250 mg/24 h</i>	<i>then: 250 mg/12 h</i>																								
19–10 mL/min	<i>then: 125 mg/48 h</i>	<i>then: 125 mg/24 h</i>	<i>then: 125 mg/12 h</i>																								
<10 mL/min (including haemodialysis and CAPD) <sup>1</sup>	<i>then: 125 mg/48 h</i>	<i>then: 125 mg/24 h</i>	<i>then: 125 mg/24 h</i>																								
Moxifloxacin Avalox® film-coated tablets 400 mg/250 mL solution for infusion	Tablet may be taken independent of meals; approx. 6 hours should be left between administration of agents containing magnesium,	Tablet must be swallowed whole Solution for infusion (dose equivalent to	No adjustment of dosage is required in individuals with mild to severely impaired renal function or in individuals on chronic dialysis, i.e. haemodialysis and continuous ambulatory peritoneal dialysis																								

	aluminium, iron or zinc and administration of moxifloxacin	tablet formulation)	
Rimstar® film-coated tablet/ Voractiv® film-coated tablet  Rifampicin 150 mg Isoniazid 75 mg Pyrazinamide 400 mg Ethambutol 275 mg	Tablets should be taken in a fasting state at least 1 hour before a meal  Tyramine- and histamine-containing foods should be avoided by individuals receiving isoniazid	Only film-coated tablets available	Rimstar should be used with caution in individuals with moderate renal impairment (creatinine clearance 30–60 mL/min); Rimstar is contraindicated in individuals with severe renal impairment (creatinine clearance <30 mL/min)  No specific recommendation for haemodialysis
Rifinah coated tablets Rifampicin 300 mg Isoniazid 150 mg  or  Rifampicin 100 mg Isoniazid 150 mg	Tablets should preferably be taken on an empty stomach at least 30 minutes before a meal or 2 hours after a meal  Tyramine- and histamine-containing foods should be avoided by individuals receiving isoniazid	Only film-coated tablets available	No specific recommendation. See individual drugs above  No specific recommendation for haemodialysis
Rifater® Tablets Rifampicin 120 mg Isoniazid 50 mg Pyrazinamide 300 mg	Tablets should preferably be taken on an empty stomach at least 30 minutes before a meal, or 2 hours after a meal  Tyramine- and histamine-containing foods should be avoided by individuals receiving isoniazid	Only tablets available	The precautions for the use of Rifater are the same as those considered when a triple individual administration of rifampicin, isoniazid and pyrazinamide is required  No specific recommendation for haemodialysis

# 12 Immune reconstitution inflammatory syndrome

---

- We recommend the use of corticosteroids tapered over 4–6 weeks in symptomatic IRIS. (GRADE 1C)
- We recommend that in recurrent IRIS, and in complex cases, advice is sought from centres with experience in managing this syndrome. (GPP)

## 12.1 Rationale

---

After starting anti-tuberculosis treatment, some individuals develop an exacerbation of symptoms, signs or radiological manifestations of TB. This has been well described in individuals without HIV infection, but appears to occur more commonly in HIV-positive individuals [1-19]. The phenomenon is known as IRIS, IRD or paradoxical reaction.

The aetiology of these reactions is unknown, but they are presumed in HIV disease to occur at least in part as a consequence of ART-related reconstitution of immunity, which leads to an abnormal immune response to tubercle antigens released by dead or dying bacilli [20-25].

## 12.2 Definition

---

IRIS does not have a generally accepted definition, although one was developed for use in resource-poor countries that is often used. Here, cases need to meet three criteria (see Appendix 7) [26].

IRIS may present in two different ways:

1. The 'paradoxical' worsening of symptoms of a known disease, either at a new body site or at the original body site, or
2. The 'unmasking' of an occult opportunistic infection, in which disease that was not clinically apparent prior to ART manifests during ART

IRIS is characterised by the worsening or appearance of new signs, symptoms or radiographic abnormalities, occurring after the initiation of ART, and not the result of TB treatment failure or another disease process. It is therefore a diagnosis of exclusion. It is often transient in duration but can last many months. It is usually seen when the TB is microbiologically controlled, but cases can occur with viable organisms isolated on culture. Some clinicians feel that there must be a significant inflammatory component to the presentation for this to be classified as IRIS.

The features of IRIS are:

- Apparent worsening/progression of TB;
- May occur at original site of disease or at remote site;
- May occur at any time after initiation of TB treatment;
- Associated with commencing or continuing ART;
- No evidence of TB relapse or recurrence (positive AFB smear does not exclude diagnosis of IRIS);
- Appropriate investigations have excluded disease attributable to other pathogens;
- Drug hypersensitivity is excluded;
- A response to corticosteroids does not confirm a diagnosis of IRIS;

## 12.3 Epidemiology of IRIS (see also Appendix 7)

---

With limited data it is difficult to predict the risk of IRIS, but the following appear to be relevant [27-31]:

- Low baseline CD4+ cell count;
- Rapid recovery in CD4+ cell count;
- Rapid decline in HIV viral load;
- Dissemination of TB outside the lung (may be attributable to high burden of bacilli);
- Short time interval between start of anti-TB treatment and initiation of ART.

## 12.4 Clinical features of IRIS

---

IRIS most often presents with fever and increased or new lymphadenopathy. The skin overlying lymph nodes is often inflamed and dusky red, and the nodes can spontaneously rupture [26]. New or worsening pulmonary lesions, pleural and pericardial effusions, ascites, psoas abscess, cutaneous lesions and new or expanding CNS tuberculomas, for example, have also been described.

A diagnosis of IRIS should be made only if TB treatment failure, drug hypersensitivity and other opportunistic infections and malignancies are excluded.

## 12.5 Management of IRIS

---

### 12.5.1 Corticosteroids

The management of IRIS may require corticosteroids, sometimes for prolonged periods, in order to control symptoms. There is no consensus on what is an optimal and effective dose to use, although prednisone or methylprednisolone have been used at a dose of 1–1.5 mg/kg, with gradual reduction after 1–2 weeks. Individuals who have been on rifampicin for 2 weeks or more will have increased liver metabolism of corticosteroids, such that the corticosteroid is effectively reduced by 33–50%. Individuals may require steroids for prolonged periods of time and IRIS may recur when the dose is reduced, necessitating higher doses. Physicians should be aware of the metabolic adverse effects and potential for serious infections, for instance local and systemic viral infections such as cytomegalovirus retinitis or Kaposi sarcoma, with high-dose corticosteroids.

A placebo-controlled study comparing the effect of steroids with that of placebo in early IRIS showed a benefit of steroids, but the data have to be interpreted with caution as a substantive proportion of those receiving placebo were treated with open-label prednisolone [32].

### 12.5.2 Other treatment options

Recurrent needle aspiration of lymph nodes or abscesses to remove pus and caseous material is appropriate if they become tense and/or inflamed. This can prevent spontaneous rupture, which may lead to long-term sinus formation and scarring.

Other treatments have as yet little evidence supporting their use. Non-steroidal anti-inflammatory agents are generally not helpful. Temporary discontinuation of antiretroviral therapy has also been advocated but can cause precipitous falls in CD4+ cell counts. Similarly, stopping anti-TB medication may have little impact on IRIS though can prolong mycobacterial treatment. Leukotriene overactivity has been implicated in IRIS, and montelukast can be considered as an alternative to steroids, but may need to be continued for a long period [33].

The efficacy of other therapies such as tocilizumab, interleukin-2, granulocyte–macrophage colony-stimulating factor and hydroxychloroquine are, as yet, unproven. A case report describes resolution of IRIS in an HIV-negative patient with use of infliximab [34].

## 12.6 References

---

1. Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. *Clin Infect Dis* 1994; **19**: 1092–1099.
2. Breen RA, Smith CJ, Bettinson H *et al*. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. *Thorax* 2004; **59**: 704–707.

3. Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. *Tubercle* 1977; **58**: 171–179.
4. Chambers ST, Hendrickse WA, Record C *et al.* Paradoxical expansion of intracranial tuberculomas during chemotherapy. *Lancet* 1984; **2**: 181–184.
5. Crump JA, Tyrer MJ, Lloyd-Owen SJ *et al.* Military tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. *Clin Infect Dis* 1998; **26**: 1008–1009.
6. Foudraine NA, Hovenkamp E, Notermans DW *et al.* Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. *AIDS* 1999; **13**: 177–184.
7. John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. *Med J Aust* 1998; **169**: 473–474.
8. Judson MA. Highly active antiretroviral therapy for HIV with tuberculosis: pardon the granuloma. *Chest* 2002; **122**: 399–400.
9. Kunimoto DY, Chui L, Nobert E, Houston S. Immune mediated 'HAART' attack during treatment for tuberculosis. Highly active antiretroviral therapy. *Int J Tuberc Lung Dis* 1999; **3**: 944–947.
10. Mofredj A, Guerin JM, Leibinger F, Masmoudi R. Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient. *Infection* 1996; **24**: 390–391.
11. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. *Am J Respir Crit Care Med* 1998; **158**: 157–161.
12. Navas E, Martin-Davila P, Moreno L *et al.* Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. *Arch Intern Med* 2002; **162**: 97–99.
13. Race EM, Adelson-Mitty J, Kriegel GR *et al.* Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. *Lancet* 1998; **351**: 252–255.
14. Ramdas K, Minamoto GY. Paradoxical presentation of intracranial tuberculomas after chemotherapy in a patient with AIDS. *Clin Infect Dis* 1994; **19**: 793–794.
15. Choremis CB, Padiatellis C, Zou Mbou Lakis D, Yannakos D. Transitory exacerbation of fever and roentgenographic findings during treatment of tuberculosis in children. *Am Rev Tuberc* 1955; **72**: 527–536.
16. Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. *Am J Med* 1999; **106**: 371–372.
17. Minguez C, Roca B, Gonzalez-Mino C, Simon E. Superior vena cava syndrome during the treatment of pulmonary tuberculosis in an HIV-1 infected patient. *J Infect* 2000; **40**: 187–189.
18. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. *Chest* 2002; **122**: 597–602.
19. Wendel KA, Alwood KS, Gachuhi R *et al.* Paradoxical worsening of tuberculosis in HIV-infected persons. *Chest* 2001; **120**: 193–197.
20. Morlese JF, Orkin CM, Abbas R *et al.* Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. *AIDS* 2003; **17**: 1411–1413.

21. Price P, Mathiot N, Krueger R *et al.* Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. *J Clin Virol* 2001; **22**: 279–287.
22. Price P, Morahan G, Huang D *et al.* Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. *AIDS* 2002; **16**: 2043–2047.
23. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. *J Infect Dis* 2001; **184**: 1073–1077.
24. Stone SF, Price P, Keane NM *et al.* Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. *HIV Med* 2002; **3**: 21–27.
25. Perez D, Liu Y, Jung T *et al.* Reconstitution of host immunity to *M tuberculosis* in HIV-infected individuals. *Am J Respir Crit Care Med* 2000; A224.
26. Meintjes G, Lawn SD, Scano F *et al.* Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis* 2008; **8**: 516–523.
27. Abdool Karim S, Naidoo K, Padayatchi N *et al.* Timing of ART during TB therapy: findings of the SAPIt Trial. *Conference on Retroviruses and Opportunistic Infections*. Boston, MA, USA.
28. Burman W, Weis S, Vernon A *et al.* Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. *Int J Tuberc Lung Dis* 2007; **11**: 1282–1289.
29. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. *J Infect* 2006; **53**: 357–363.
30. Michailidis C, Pozniak AL, Mandalia S *et al.* Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. *Antivir Ther* 2005; **10**: 417–422.
31. Shelburne SA, Visnegarwala F, Darcourt J *et al.* Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. *AIDS* 2005; **19**: 399–406.
32. Meintjes G, Wilkinson RJ, Morroni C *et al.* Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. *AIDS* 2010; **24**: 2381–2390.
33. Hardwick C, White D, Morris E *et al.* Montelukast in the treatment of HIV associated immune reconstitution disease. *Sex Transm Infect* 2006; **82**: 513–514.
34. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. *Clin Infect Dis* 2008; **47**: e83–85.

# 13. Pregnancy and breastfeeding

---

- We recommend that pregnant and breastfeeding women with drug-sensitive TB are treated with standard first-line anti-tuberculosis therapy. (GRADE 1C)

## 13.1 Rationale

---

Women with active TB should be treated in pregnancy. However, there are insufficient data on the safety, tolerability and efficacy of TB treatment in pregnancy. During pregnancy, there are many changes in pharmacokinetics and TDM of anti-tubercular drugs may be advisable.

Rifampicin levels are slightly higher in pregnancy, suggesting no dose adjustments are necessary [1]. Rifampicin does not decrease efavirenz (EFV) exposure in pregnancy and standard doses of EFV should be used [2].

For the first-line drugs rifampicin, ethambutol and pyrazinamide, there are no available data to suggest teratogenic effects or need for dose adjustment. There are no data for rifabutin in women, although there were no teratogenic effects in rats or rabbits. Isoniazid is not teratogenic even when used in the first 4 months of pregnancy [3].

Pregnant women may also be at increased risk of peripheral neuropathy with isoniazid and should be offered standard treatment with pyridoxine 10–25mg daily [4].

Treatment of MDRTB should be supervised by clinicians with expertise in the field.

Streptomycin, amikacin and kanamycin can cause congenital deafness [5] and prothionamide is teratogenic, so both should be avoided. Ethionamide causes birth defects at high doses in animals [6]. Bedaquiline has a Class B pregnancy category and could be considered for use in pregnant women, but safety has not yet been established [7]. Delamanid is available on compassionate use in pregnancy.

Pregnant women should be tested for latent TB in the same way as non-pregnant women (see Section 6). In a UK setting the current guidelines suggest testing with IGRA only. Thresholds for interpretation of TST and IGRA do not change during pregnancy, although in pregnancy there is considerable discordance between TST and IGRA screening results.

It is extremely important to exclude active disease, especially for those at risk of being recently infected with TB, or who have a low CD4+ cell count, to prevent haematogenous spread of *M. tuberculosis* to the placenta and active TB peri-/postpartum.

Isoniazid given as treatment for latent TB infection does not usually cause significant hepatotoxicity [3,8] and does not seem to be associated with adverse pregnancy outcomes, but the number of women studied is small [3]. Isoniazid is therefore recommended as chemopreventative treatment even during the first trimester for pregnant women who have likely been infected recently, and are therefore at higher risk of disease progression, to prevent the haematogenous spread of *M. tuberculosis* to the placenta (see Section 6). For pregnant women with less likelihood of progression to active disease, isoniazid can be deferred until after delivery [9].

UK guidelines recommend against HIV-positive mothers breastfeeding, but some women may choose to do so if they continue suppressive ART. Tuberculosis treatment is in itself not a contraindication to breastfeeding if the woman is deemed non-infectious, and is being treated with first-line agents [10]. Anti-tuberculosis drugs are present in breast milk but only at low concentrations and therefore appear to be safe [11].

- In women of childbearing age, offer contraception as part of TB care, particularly MDR care. (GPP)

## 13.2 References

---

1. Denti P, Martinson N, Cohn S *et al*. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. *Antimicrob Agents Chemother* 2015; **60**: 1234–1241.
2. Dooley KE, Denti P, Martinson N *et al*. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. *J Infect Dis* 2015; **211**: 197–205.
3. Taylor AW, Mosimaneotsile B, Mathebula U *et al*. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. *Infect Dis Obstet Gynecol* 2013; **2013**: 195637.
4. World Health Organization. *Guidelines for treatment of tuberculosis. 4th edn*. 2010. Available at: <http://www.who.int/tb/publications/2010/9789241547833/en/> (accessed March 2017).
5. Snider DE, Jr., Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. *Am Rev Respir Dis* 1980; **122**: 65–79.
6. Dluzniewski AG-L, G; . The search for teratogenic activity of some tuberculostatic drugs. *Dissertationes Pharmaceuticae et Pharmacologicae* 1971; **23**: 383–392.
7. Centers for Disease Control Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. *MMWR Recomm Rep* 2013; **62**: 1–12.
8. Tiam A, Machezano R, Gounder CR *et al*. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. *J Acquir Immune Defic Syndr* 2014; **67**: e5–e11.
9. Getahun H, Sculier D, Sismanidis C *et al*. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. *J Infect Dis* 2012; **205 Suppl 2**: S216–227.
10. de Ruiter A, Taylor GP, Clayden P *et al*. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). *HIV Med* 2014; **15 Suppl 4**: 1–77.
11. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. *Clin Infect Dis* 2012; **55**: 1532–1549.

## 14. Prevention and control of transmission

---

- We recommend that all hospitals and HIV units have a TB infection control plan, which includes adequate protection of healthcare workers and other contacts. (GRADE 1B)

For good control of TB there should be:

- Recognition that TB is a potential diagnosis;
- Early diagnosis and active case finding;
- Timely commencement of treatment with an appropriate drug regimen;
- Treatment support including DOT;
- Early consideration of drug resistance in non-responding patients;
- Awareness of social and cultural barriers to accessing health services.

### 14.1 Hospital care of individuals with potential or known TB requires: considerations

---

Unless there is a clear clinical or public health need, such as homelessness, people with suspected infectious or confirmed pulmonary TB should not be admitted to hospital for diagnostic tests or for care.

Do not admit people with suspected infectious or confirmed pulmonary TB to a ward containing people who are immunocompromised, including people with HIV, unless they can be cared for in a negative pressure room on the same ward.

In people who may have TB, only carry out aerosol-generating procedures such as bronchoscopy, sputum induction or nebuliser treatment in an appropriately engineered and ventilated area (ideally a negative pressure room).

Minimise the number and duration of visits a person with TB makes to an outpatient department while they are still infectious. To minimise the risk of infection, people with infectious TB should be seen at times or in places away from other (especially immunocompromised) people.

Care for people deemed to be at low risk:

- In a single room, as a minimum.

For people deemed to be at high risk:

- Provide care in a monitored negative pressure room; and
- Have specimens sent for rapid diagnostic tests, such as nucleic acid amplification tests (see Section 5 and Appendix 3).

Care for people with a continuing clinical or public health need for admission with pulmonary TB in a single room (as a minimum) until they have completed 2 weeks of the standard treatment regimen.

Consider de-escalating isolation after 2 weeks of treatment, taking into account the risks and benefits.

### 14.2 Adequate protection of healthcare workers and other contacts

---

- Appropriate isolation of infectious patients;
- Risk assessment for drug resistance;
- Adequate negative pressure rooms that are properly monitored;
- Aerosol-generating procedures (bronchoscopy, sputum induction or nebuliser treatment) should only take place in negative pressure rooms;
- Consider all individuals potentially infectious until proven otherwise;
- No mixing of HIV-infected or other immunosuppressed individuals with TB patients;

- Hospital TB control plan based on risk assessment;
- Adequate protection of healthcare workers and other contacts.

### 14.3 Recommended reading

---

Guidelines for the prevention and control of transmission of TB include:

- NICE: Tuberculosis, clinical diagnosis and management of TB, and measures for its prevention and control, 2016. Available at: [www.nice.org.uk/guidance/ng33/chapter/Recommendations#infection-control](http://www.nice.org.uk/guidance/ng33/chapter/Recommendations#infection-control). See also: [www.gov.uk/government/collections/tuberculosis-and-other-mycobacterial-diseases-diagnosis-screening-management-and-data](http://www.gov.uk/government/collections/tuberculosis-and-other-mycobacterial-diseases-diagnosis-screening-management-and-data)
- Public Health England: Tuberculosis (TB): collaborative strategy, 2015. Available at: [www.gov.uk/government/publications/collaborative-tuberculosis-strategy-for-england](http://www.gov.uk/government/publications/collaborative-tuberculosis-strategy-for-england)
- WHO policy on TB infection control in health-care facilities, congregate settings and households, 2009. Available at: [www.who.int/tb/publications/tb-facilities-policy/en/](http://www.who.int/tb/publications/tb-facilities-policy/en/)
- Department of Health: Tuberculosis prevention and treatment, a toolkit for planning, commissioning and delivering high-quality services in England, 2007. Available at: [http://webarchive.nationalarchives.gov.uk/20130123192158/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_075621](http://webarchive.nationalarchives.gov.uk/20130123192158/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_075621)
- The Interdepartmental Working Group on Tuberculosis: The prevention and control of tuberculosis in the United Kingdom, 1998. Available at: [http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_4006196](http://webarchive.nationalarchives.gov.uk/+http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4006196)

## 15. Notification/tracing of contacts

---

- We recommend that once a person has been diagnosed with active TB, the diagnosing physician should inform relevant colleagues so that the need for contact tracing can be assessed without delay. Contact tracing should not be delayed until notification. (GRADE 1B)
- We recommend screening the close contacts of any person with pulmonary or laryngeal TB. (GRADE 1B)

### 15.1 NICE guidelines [1]

---

In asymptomatic close contacts older than 65 years, consider a chest X-ray (if there are no contraindications), possibly leading to further investigation for active TB.

Do not routinely assess social contacts of people with TB, who will include most workplace contacts.

### 15.2 Assessing the need for tracing social contacts of people with pulmonary or laryngeal TB

---

- This should be done when the index case is judged to be particularly infectious (for example, evidenced by transmission to close contacts); or
- Any social contacts are known to possess features that put them at high risk of going on to develop active TB.

### 15.3 Offer 'inform and advise' information to all contacts of people with smear-positive TB

---

The management of contacts of MDRTB individuals needs to be guided by a comprehensive individual risk assessment that takes into consideration the balance between risk and benefits for the individual. Strict clinical observation and close monitoring for the development of active TB disease for at least 2 years is an alternative to provision of preventive treatment for contacts with MDRTB cases. (See also Section 5.)

### 15.3 Notification

---

TB is a notifiable disease in the UK, as it is in many other countries.

If the patient is concerned about disclosure of HIV status following notification by an HIV physician, then the notification can be done by any physician involved in clinical care.

### 15.4 References

---

1. NICE. *Tuberculosis. NICE guideline [NG33]*. 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).

## 16. Death and clinico-pathological audit

---

Despite diagnosis and treatment, individuals with HIV and TB infection still die. Some arrive moribund as late presenters and the diagnosis is made at autopsy. Autopsy examination in individuals with known HIV/TB co-infection is useful: it categorises the extent (often underestimated clinico-radiologically) and the pathological type of disease; it enables audit of medical practice.

The causes of death in HIV/TB include:

- Active progressive TB, causing lethal critical organ damage and/or systemic septic shock;
- Secondary effects of TB, e.g. lung haemorrhage, meningo-vascular obstruction and stroke;
- IRIS affecting one or more critical organs, e.g. lung, brain;
- Anti-TB drug toxicity, e.g. in the liver;
- Other HIV- or non-HIV-related comorbidities in a person effectively treated for TB, which influenced why the person died;
- Other fatal disease in a person diagnosed with and treated for TB, without laboratory confirmation, who shows at autopsy no evidence of having had TB.

At autopsy, culture of tuberculous tissue should be performed routinely, to evaluate drug sensitivity and bacterial viability.

Autopsies in the UK and Ireland are either requested by clinicians or commanded by a coroner or procurator fiscal (in Scotland). If the autopsy is coronial, every endeavour should be made to obtain the report for clinical audit. At the time of autopsy, discussion with the pathologist is helpful to clarify the clinico-pathological issues and so optimise the utility of the outcome of the examination.

# 17. Appendices

## Appendix 1. Summary of the modified GRADE system

BHIVA revised and updated the Association’s guideline development manual in 2011 [1]. BHIVA has adopted the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for the assessment, evaluation and grading of evidence and the development of recommendations [2,3].

<p><b>1A</b> Strong recommendation. High-quality evidence. Benefits clearly outweigh risk and burdens, or vice versa. Consistent evidence from well-performed, randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. Strong recommendations, can apply to most individuals in most circumstances without reservation. Clinicians should follow a strong recommendation unless there is a clear rationale for an alternative approach.</p>	<p><b>2A</b> Weak recommendation. High-quality evidence. Benefits closely balanced with risks and burdens. Consistent evidence from well-performed randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. Weak recommendation, best action may differ depending on circumstances or individuals or societal values.</p>
<p><b>1B</b> Strong recommendation. Moderate-quality evidence. Benefits clearly outweigh risk and burdens, or vice versa. Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise), or very strong evidence of some other research design. Further research may impact on our confidence in the estimate of benefit and risk. Strong recommendation and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.</p>	<p><b>2B</b> Weak recommendation. Moderate-quality evidence. Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens. Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise). Further research may change the estimate of benefit and risk. Weak recommendation, alternative approaches likely to be better for some individuals under some circumstances.</p>
<p><b>1C</b> Strong recommendation. Low-quality evidence. Benefits appear to outweigh risk and burdens, or vice versa. Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality.</p>	<p><b>2C</b> Weak recommendation. Low-quality evidence. Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. Weak recommendation; other alternatives may be reasonable.</p>
<p><b>1D</b> Strong recommendation. Very low-quality evidence. Benefits appear to outweigh risk and burdens, or vice versa. Evidence limited to case studies. Strong recommendation based only on case studies and expert judgement.</p>	<p><b>2D</b> Weak recommendation. Very low-quality evidence. Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. Evidence limited to case studies and expert judgement. Very weak recommendation; other alternatives may be equally reasonable.</p>

### References

1. British HIV Association. *BHIVA Guideline Development Manual*. 28 January 2014. Available at: <http://www.bhiva.org/GuidelineDevelopmentManual.aspx> (accessed August 2015).
2. GRADE Working Group. Grading the quality of evidence and the strength of recommendations. Available at: <http://www.gradeworkinggroup.org/intro.htm> (accessed August 2015).

3. Guyatt GH, Oxman AD, Kunz R *et al.* Going from evidence to recommendations. *BMJ* 2008; **336**: 1049–1051.

Consultation draft

## Appendix 2. Systematic literature search

---

### *QUESTIONS and PICO criteria*

Databases searched: Medline, Embase, Cochrane Library

Conference abstracts searched:

- The Union World Conference against Lung Disease (IUATLD)
- IAS Conference on HIV Pathogenesis and Treatment
- International AIDS Conference
- Conference on Retroviruses and Opportunistic Infections
- European Conference on Clinical Aspects and Treatment of HIV Infection
- International Congress on Drug Therapy in HIV Infection
- British HIV Association Annual Conference
- International Conference on Antimicrobial Agents and Infectious Disease ICAAC

Date parameters:

- Databases: 2011–June 2015
- Conference abstracts: 2013–July 2015

Systemic literature searches were undertaken from published work and conference abstracts up until June 2015 as described in the BHIVA guidelines development manual.

The population was defined as HIV-positive adults affected by tuberculosis.

Search questions were set by the Writing Group within each search as listed below.

### *Search 1: Diagnosing active TB in HIV-infected adults*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with suspected tuberculosis

Intervention: diagnosing presence of active TB

Comparator: none

Outcomes: TB treatment

1. Pulmonary TB diagnosis
  - What clinical signs, symptoms or risk factors are suggestive of active pulmonary TB?
  - What is the optimal diagnostic test for active pulmonary TB?
  - In the presence of a negative culture, what other tests support an accurate positive diagnosis in subjects with suspected respiratory TB?
  - Is there a difference in diagnostic accuracy according to the level of immunosuppression?
2. Extra-pulmonary TB diagnosis (EPTB)
  - What clinical signs, symptoms or risk factors are suggestive of active EPTB?
  - What is the optimal diagnostic test for EPTB in HIV?
  - In the presence of a negative culture, what other tests support an accurate positive diagnosis in subjects with suspected respiratory TB?
  - Is there a difference in diagnostic accuracy according to the level of immunosuppression?
3. MDR TB
  - What are the relative risk factors associated with resistance or MDR?
  - What is the optimal method to diagnose MDR TB?

### *Search 2: Latent TB in HIV-infected adults*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals exposed to tuberculosis

Intervention: prevention of TB

Comparator: none

Outcomes: death, morbidity, TB transmission, drug resistance

1. Diagnosis of latent TB
  - Who should be screened for latent TB?
  - How should latent TB be diagnosed in HIV-infected adults?
2. Treatment of latent TB
  - Who should be treated for latent TB?
  - What is the optimal treatment for latent TB in HIV?
  - What is the optimal duration of treatment?

### *Search 3: Treatment of active TB in HIV*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with active tuberculosis

Intervention: TB treatment

Comparator: none

Outcomes: death, morbidity, TB transmission, drug resistance

1. Full sensitive TB
  - What anti-tubercular treatment should be recommended?
  - Are there differences in treatment in pulmonary/EPTB?
  - What is the optimal duration of treatment in pulmonary TB?
  - What is the optimal duration of treatment in EPTB?
  - When should rifabutin be used?
  - When should rifapentine be used?
  - When should steroids be used?
  - Are intermittent dosing regimens as effective as daily drug treatment regimens in reducing mortality and morbidity?
  - MDR/XDR TB
    - What anti-tubercular treatment should be recommended?
    - What is the optimal duration of treatment according to the different resistance profiles?
  - Treatment interruptions
    - What is the best approach to re-establish appropriate treatment for people receiving drug treatment for active TB who experience treatment interruptions?
  - TDM
    - What is the role of TDM?
2. DOT
  - What is the role for DOT?

### *Search 4: Drug toxicity*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with active tuberculosis

Intervention: management of toxicity

Comparator: none

Outcomes: death, morbidity

1. Hepatotoxicity
  - How is hepatotoxicity defined?
  - When does hepatotoxicity generally occur?
  - What is the best management of hepatotoxicity?
  - Pre-existing liver disease
  - What routine screen should be performed?
  - Who is at greater risk of hepatotoxicity?
  - How is hepatotoxicity recognised in individuals with pre-existing liver disease?
  - What is the optimal treatment in individuals with pre-existing liver disease?
  - Gastrointestinal side effects
  - When does gastrointestinal toxicity generally occur?
  - What is the best management of gastrointestinal toxicity?
  - Peripheral neuropathy
  - When does peripheral neuropathy occur?
  - Should ART be changed in individuals experiencing peripheral neuropathy?
  - What is the best management of peripheral neuropathy?
  - Rash
  - When does rash generally occur?
  - What is the best management in case of rash?

### *Search 5: Starting ART*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with tuberculosis

Intervention: starting antiretroviral therapy in individuals affected by tuberculosis

Comparator: none

Outcomes: death, TB-associated morbidity, AIDS, non-AIDs co-morbidities

1. Starting ART
  - What is the optimal timing to start antiretroviral treatment in antiretroviral-naïve adult individuals on treatment for tuberculosis?
2. Antiretroviral-naïve patients
  - Is there robust evidence that one antiretroviral regimen is superior to others?
  - Should the regimen be changed after the end of tuberculosis treatment?
3. Pharmacokinetics: individuals on ART
  - Should ARV drugs and dosages be altered in case of concomitant treatment for tuberculosis?

### *Search 6: Diagnosing and managing immune reconstitution inflammatory syndrome (IRIS)*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with active tuberculosis

Intervention: TB treatment

Comparator: none

Outcomes: death, morbidity

1. Diagnosis
  - Who is at higher risk of developing IRIS?
  - Which are common manifestations of IRIS?
  - What are the optimal diagnostic methods to identify IRIS?
2. Treatment
  - How is IRIS best treated?
  - Should ART ever be interrupted?

### *Search 7: Treatment failure and relapse*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: HIV individuals with active tuberculosis

Intervention: TB treatment

Comparator: none

Outcomes: death, morbidity, TB transmission, drug resistance

1. Treatment failure
  - How is treatment failure defined?
  - What is the optimal management of treatment failure?
2. Relapse
  - How is relapse defined?
  - What is the optimal management of TB relapse?

### *Search 8: Pregnant and breastfeeding women with TB/HIV*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: Pregnant/breastfeeding HIV individuals with active tuberculosis

Intervention: TB treatment

Comparator: none

Outcomes: fetal death, fetal death morbidity, TB transmission, morbidity, death

1. Pregnant women
  - When should TB treatment start?
  - What is the optimal treatment for pregnant women?
  - What are the risks for the foetus?
2. Breastfeeding women
  - What is the optimal management of women who are breastfeeding?
  - What are the risks for the child?

### *Search 9: Prevention and control of transmission*

Study design: Systematic reviews (SRs), randomised control trials (RCTs), observational, risk, economic

Population: general population

Intervention: prevention of TB transmission

Comparator: none

Outcomes: latent TB infection, active TB infection

1. Isolation
  - In which situations (and for how long) should patients be put in isolation room?
  - How should aerosol-producing procedures be performed in order to contain transmission?
2. Notification
  - When should a notification be made?
  - Who should perform the notification?
3. Tracing contacts
  - When should contacts of a patient with TB be traced?
  - How should the tracing be performed?
4. Risk assessment
  - How should a risk assessment be carried out?
  - What kind of screening (and how often) should be performed in healthcare workers?

The following Appendices contain additional information that the writing group used to base their decisions.

## Appendix 3. Diagnosis of active TB/HIV (diagnostic tests)

---

### *Use of Rapid PCR testing*

#### *Pulmonary disease*

Xpert MTB/RIF has higher sensitivity for TB detection in smear-positive than smear-negative patients, and when used in combination with smear microscopy and can increase TB detection by 23%.

The WHO performed a systematic review on diagnostic accuracy in pulmonary TB [1]. A total of 9558 participants, in 27 studies, were included in the review. The reference standard for detecting pulmonary TB was culture (solid or liquid).

When used as an initial diagnostic test replacing smear microscopy, Xpert MTB/RIF achieved an overall pooled sensitivity of 88% (95% credible interval [2]: 84–92%) and a pooled specificity of 99% (95% CrI: 98–99%) (22 studies, 9008 participants).

When used as an add-on test following a negative smear-microscopy result, Xpert MTB/RIF yielded a pooled sensitivity of 68% (95% CrI: 61–74%) and a pooled specificity of 99% (95% CrI: 98–99%) (23 studies, 7151 participants). For smear-positive culture-positive TB, the pooled sensitivity of Xpert MTB/RIF was 98% (95% CrI: 97–99%) (23 studies, 1952 participants); for smear-negative culture-positive TB, the pooled sensitivity was 68% (95% CrI: 61–74%) (23 studies, 7151 participants).

For people living with HIV, the pooled sensitivity of Xpert MTB/RIF was 79% (95% CrI: 70–86%) (seven studies, 1789 participants); for people without HIV infection, the pooled sensitivity was 86% (95% CrI: 76–92%) (seven studies, 1470 participants).

#### *CNS TB*

A systematic review conducted by the WHO on the sensitivity and specificity of molecular methods (Xpert MTB/RIF) for the detection of TBM [3] showed a pooled sensitivity across studies of 79.5% (95% CI: 62.0–90.2%), and a pooled specificity of 98.6% (95% CI: 95.8–99.6%). In this review a total 709 CSF samples (in 16 studies) were tested with Xpert MTB/RIF, and the results were compared against culture as a reference standard. Another systematic review found similar results for sensitivity of Xpert in detection on TBM, with a median sensitivity of 85% (IQR: 0.75–1.00) [4], and a pooled sensitivity of 81% (95% CI: 0.59–0.92), respectively [5]. In particular, higher sensitivity and specificity is found when concentrated CSF is analysed compared to unconcentrated samples (84.2% vs. 51.3%, 98% vs. 94.6%, respectively) [5].

#### *Pleural TB*

A meta-analysis of 63 studies found a sensitivity of 92% and specificity of 90% of ADA in the diagnosis of pleural TB [6]. The level of ADA correlates with the probability of having pleural TB, with the most accepted cut-off value being of 40 U/L [7]: a diagnosis of pleural tuberculosis is highly probable if the fluid ADA is above 70 U/L and the pleural fluid has a lymphocyte-to-neutrophil ratio greater than 0.75.

A presumptive diagnosis of tuberculous pleuritis can be made if the pleural fluid ADA is between 40 and 70 U/L and the patient has a lymphocyte-to-neutrophil ratio of more than 0.75.

While the level of immunity seems to inversely correlate with the presence of mycobacteria in the pleural fluid, with higher positive smears and positive culture samples in immunodeficient patients, a low CD4+ cell count does not correlate with sensitivity of this test [8]. We suggest sending pleural fluid for microscopy and culture, and quantification of ADA in pleural fluid.

#### *Extrapulmonary TB*

A systematic review [4] analysed 27 studies (with a total of 6026 non-respiratory samples), including studies

enrolling HIV-positive subjects. Xpert reliably detected the vast majority of non-respiratory samples testing smear-positive, culture-positive for *M. tuberculosis*, but only approximately two-thirds of smear-negative samples. The overall specificity was found to be very high across the majority of studies, whereas sensitivity was found to be extremely heterogeneous, depending also on the type and quality of tissue/sample. Sensitivity ranged between 25% and 100% when Xpert and culture were both applied to the index non-respiratory samples. Much higher sensitivity was seen when testing lymph node samples, other tissue samples and cerebrospinal fluid compared to the results of testing pleural fluid and other serous fluids. To note, high sensitivity was also observed when testing gastric aspirate samples. Another systematic review and meta-analysis [5] analysed 18 studies (evaluating 4461 samples) and found no differences in diagnostic accuracy between studies with >10% versus <10% HIV-positive individuals. However, in some studies a very high sensitivity of Xpert detection of EPTB in lymph node tissue was found in HIV subjects, both dependently and independently of CD4+ cell count. Other studies [9,10] assessing the utility of Xpert in detecting disseminated disease from urine in HIV-infected individuals showed a strong inverse association between Xpert sensitivity and CD4+ cell count: sensitivity increased to 60% in individuals with CD4+ count <100 cells/mm<sup>3</sup> [10]. These results demonstrate that urine-based diagnosis may be particularly useful for routine investigation among HIV-infected individuals with advanced infection.

### MDR/XDR

MDR/XDR TBA systematic review [11] of 56 studies on the diagnostic accuracy of molecular genetic tests for drug resistance has shown that rapid molecular tests for rifampicin and isoniazid resistance are sensitive, specific and cost-effective when added to culture drug susceptibility testing.

Pooled sensitivity for GenoType® MTBDRplus (Hain Lifescience, Nehren, Germany) was 83.4% for isoniazid and 94.6% for rifampicin resistance, for INNO-LiPARif.TB® (Fujirebio Europe, Ghent, Belgium) was 95.4% for rifampicin resistance, and for Xpert® MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) was 96.8% for rifampicin resistance; equivalent pooled specificity was 99.6%, 98.2%, 99.7% and 98.4%, respectively.

When used to detect rifampicin resistance, Xpert MTB/RIF achieved a pooled sensitivity of 95% (95% CrI: 90–97%) (17 studies, 555/2624 total specimens) and a pooled specificity of 98% (95% CrI: 97–99%) (24 studies, 2414 specimens, including true negatives and false positives).

### Antigen testing—urine LAM

The urine lateral flow lipoarabinomannan (LF-LAM) assay is a point-of-care (POC) test for active TB (AlereDetermine™ TB LAM Ag, AlereInc, Waltham, MA, USA), commercialised in January 2013. The test detects lipoarabinomannan (LAM), a lipopolysaccharide present in mycobacterial cell walls, released from metabolically active or degenerating bacterial cells. This antigen appears to be present only in people with active TB disease. The advantages of the test are its simplicity and speed of use, lack of instrumentation, low cost and its implementation at the point of care.

It represents a useful add-on diagnostic tool for subjects with difficulty producing any sputum, with extrapulmonary forms of TB, as often is the case in advanced HIV immunodeficiency.

In a study conducted in South Africa on 602 HIV adults screened for TB, Determine TB-LAM had highest sensitivity at low CD4+ cell counts: 66.7% at <50 cells/mm<sup>3</sup>, 51.7% at <100 cells/mm<sup>3</sup>, and 39% at <200 cells/mm<sup>3</sup>; specificity was greater than 98% for all strata. When combined with smear microscopy, sensitivity was 72.2% at CD4+ cell counts <50 cells/mm<sup>3</sup>, 65.5% at <100 cells/mm<sup>3</sup>, and 52.5% at <200 cells/mm<sup>3</sup> [12]. Although characterised by limited sensitivity (and therefore required to be used in conjunction with microscopy and molecular tests), it provides the most rapid means of conducting an initial diagnostic screen at the point of care. It has lower specificity than the molecular diagnostic tests, and false positive tests can result from cross-reaction with a number of other bacteria, including those present in oral flora such as various species of *Actinobacteria* (*Nocardia* and *Streptomyces*), *Candida* and non-tuberculous mycobacteria [13].

A Cochrane review is currently ongoing with the objective of assessing the accuracy of this test for the diagnosis of active TB in adults with HIV, which will help define its role in the diagnostic/screening process of TB in HIV [14].

Few systematic reviews have evaluated the role of IGRAs in diagnosing active tuberculosis in HIV-infected patients [15-18]: results are consistent in showing a sensitivity of QFT-GIT of approximately 65% and a sensitivity of about

70% for T-SPOT.TB. However, there is no consistent evidence that the IGRAs are more sensitive for detecting tuberculosis in individuals with active disease. Data from the five studies reporting comparisons between QFT-GIT and TST yielded a pooled sensitivity of 67% and 60%, respectively.

## References

1. Steingart KR, Schiller I, Horne DJ *et al.* Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 2014; **1**: CD009593.
2. Riza AL, Pearson F, Ugarte-Gil C *et al.* Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. *Lancet Diabetes Endocrinol* 2014; **2**: 740–753.
3. World Health Organization. *Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update.* Geneva: 2013. Available at: <http://apps.who.int/iris/handle/10665/112472> (accessed January 2018).
4. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. *BMC Infect Dis* 2014; **14**: 709.
5. Denkinger CM, Schumacher SG, Boehme CC *et al.* Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2014; **44**: 435–446.
6. Liang QL, Shi HZ, Wang K *et al.* Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. *Respir Med* 2008; **102**: 744–754.
7. Porcel JM. Tuberculous pleural effusion. *Lung* 2009; **187**: 263–270.
8. Baba K, Hoosen AA, Langeland N, Dyrholm-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. *PLoS One* 2008; **3**: e2788.
9. Lawn SD, Kerkhoff AD, Vogt M, Wood R. High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. *J Acquir Immune Defic Syndr* 2012; **60**: 289–294.
10. Peter JG, Theron G, Muchinga TE *et al.* The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. *PLoS One* 2012; **7**: e39966.
11. Drobniewski F, Cooke M, Jordan J *et al.* Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. *Health Technol Assess* 2015; **19**: 1–188, vii–viii.
12. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. *Lancet Infect Dis* 2012; **12**: 201–209.
13. Lawn SD, Dheda K, Kerkhoff AD *et al.* Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. *BMC Infect Dis* 2013; **13**: 407.
14. Shah M, Hanrahan C, Wang Zhuo Y *et al.* Urine lateral flow lipoarabinomannan assay for diagnosing active tuberculosis in adults living with HIV. John Wiley & Sons, Ltd, 2014. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011420/abstract> (accessed
15. Cattamanchi A, Smith R, Steingart KR *et al.* Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; **56**: 230–238.

16. Chen J, Zhang R, Wang J *et al.* Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systematic review and meta-analysis. *PLoS One* 2011; **6**: e26827.
17. Metcalfe JZ, Everett CK, Steingart KR *et al.* Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. *J Infect Dis* 2011; **204 Suppl 4**: S1120–1129.
18. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. *PLoS One* 2012; **7**: e32482.

Consultation draft

## Appendix 4. Chemopreventive therapy

---

### Excluding active TB

Before testing for, or treating LTBI, active TB should be excluded with a detailed history and examination.

Results from a meta-analysis of 12 observational studies, nine of which were based in Africa and three in South-east Asia, including over 8000 HIV-positive participants, showed that individuals reporting none of current cough, night sweats, fever or weight loss have a very low probability of having active TB (negative predictive value of 97.7% at 5.0% TB prevalence among people living with HIV) [1].

### Interferon-gamma release assays (IGRAs)

Interferon-gamma release assays (IGRAs) are blood tests that measure interferon-gamma release from T cells after stimulation with antigens largely specific to *M. tuberculosis* (such as early secreted antigen target [ESAT-6] and culture filtrate protein [CFP-10]) [2]. The current commercially available tests are the T-Spot.TB (Oxford Immunotec, Abingdon, Oxfordshire, UK), which uses enzyme-linked immunosorbent spot (ELISPOT) technology to detect the antigen-specific T cells, and the QuantiFERON-TB Gold (QFT-GIT) and QuantiFERON-TB Gold Plus (Qiagen, Manchester, UK) which are enzyme-linked immunosorbent assays.

All tests are approved for the diagnosis of LTBI in HIV-negative individuals. There are some differences between the two test platforms although in general they are unaffected by previous BCG immunisation and infection with most non-tuberculous mycobacteria (an important exception in the UK being *Mycobacterium kansasii*).

The risk of tuberculosis in the short- to medium-term in HIV-positive adults with a negative QFT-GIT seems to be low [3]. However, indeterminate or borderline IGRA results are more common in HIV-positive individuals as HIV-associated immunosuppression, measured by circulating CD4+ T cell count, reduces the ability of IGRAs (both QFT-GIT, and to a lesser extent, T-SPOT.TB) to detect LTBI and reversions/conversions occur close to cut-off values [4,5].

TST can also identify individuals with LTBI and those who benefit from treatment in high tuberculosis-incidence settings [6] but false-negative TST results were shown to be more common among HIV-positive individuals in the pre-ART era, especially in those with low CD4+ cell counts [7-11]. False positives occur after BCG immunisation or following exposure to non-tuberculous mycobacteria.

A Cochrane review including 12 trials with a total of 8578 randomised participants located across a spectrum of low to high TB-incidence countries found that treating LTBI in HIV-positive individuals with a positive TST is effective in reducing the incidence of active TB (relative risk 0.38, 95% CI: 0.25-0.57) [12]. Efficacy was similar for all regimens, regardless of drug or duration of therapy, although shorter, multidrug regimens were associated with more discontinuation due to adverse effects than longer isoniazid-only regimens. However, the great majority of participants were not using effective ART when the studies of LTBI therapy were performed.

### References

1. Getahun H, Kittikraisak W, Heilig CM *et al*. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. *PLoS Med* 2011; **8**: e1000391.
2. Chapman AL, Munkanta M, Wilkinson KA *et al*. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of *Mycobacterium tuberculosis*-specific T cells. *AIDS* 2002; **16**: 2285–2293.
3. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. *PLoS One* 2012; **7**: e32482.
4. Cattamanchi A, Smith R, Steingart KR *et al*. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. *J Acquir Immune Defic Syndr* 2011; **56**: 230–238.

5. Pullar ND, Steinum H, Bruun JN, Dyrhol-Riise AM. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study. *BMC Infect Dis* 2014; **14**: 667.
6. Samandari T, Agizew TB, Nyirenda S *et al*. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011; **377**: 1588–1598.
7. Graham NM, Nelson KE, Solomon L *et al*. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. *JAMA* 1992; **267**: 369–373.
8. Markowitz N, Hansen NI, Wilcosky TC *et al*. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. *Ann Intern Med* 1993; **119**: 185–193.
9. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. *Clin Infect Dis* 1994; **19**: 26–32.
10. Johnson MP, Coberly JS, Clermont HC *et al*. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. *J Infect Dis* 1992; **166**: 194–198.
11. Yanai H, Uthairavit W, Mastro TD *et al*. Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. *Int J Tuberc Lung Dis* 1997; **1**: 427–434.
12. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. *Cochrane Database Syst Rev* 2010; CD000171.

## Appendix 5. Treatment of drug-sensitive TB: drug regimens

---

The treatment of drug-susceptible tuberculosis evolved through an international clinical trial programme to the current standard of care: short-course chemotherapy, consisting of 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol (intensive phase), followed by 4 months of rifampicin and isoniazid (continuation phase) (2RHZE/4RH). These studies were conducted in the era before HIV co-infection in TB individuals became widespread. A clinical trial in the pre-ART era, which compared 6 versus 12 months of short course chemotherapy, was limited by high mortality but showed high rates of recurrent TB with 2RHZE/4RH [1]. Subsequent studies reported that recurrent TB in HIV-positive individuals is usually due to re-infection; relapse rates after 2RHZE/4RH were no more common than those observed in HIV-negative individuals [2-4]. Short-course chemotherapy thus became the standard of care irrespective of HIV status. Several recent attempts to shorten TB therapy to 4 months (for instance, by using fluoroquinolones) have proved unsuccessful, with high relapse rates [5-8]. Intermittent administration of TB therapy should be avoided during the induction phase, as this strategy has been associated with acquired rifamycin resistance [9].

Pyrazinamide is an essential component of short-course chemotherapy [10-12]; the duration of TB treatment should be extended to 9 months for individuals who are unable to take pyrazinamide.

Individuals with positive TB cultures at the end of the intensive phase are at increased risk of relapse [13]. Poor adherence should be re-assessed, drug susceptibility testing conducted, and treatment extended to 9 months.

There is no evidence that individuals with disseminated TB should receive more prolonged therapy. Many clinicians use extended treatment regimens (up to 12 months as per NICE guidance [14]) for central nervous system tuberculosis (i.e. tuberculous meningitis) even though 6–9 months appears to be sufficient [15,16].

Rifabutin is a rifamycin with similar activity against *M. tuberculosis* as rifampicin [17-19] although no trials have been conducted in individuals receiving ART. The main advantage of rifabutin is that it allows the co-administration of (ritonavir-boosted) protease inhibitors (see Sections 9 and 10). The optimal dose of rifabutin in individuals who receive PI/r has not been established [20]. The currently recommended dose of 150 mg/day results in adequate rifabutin exposure but 15-fold increased exposure of rifabutin metabolites. Good clinical outcomes have been reported with reduced dose rifabutin (150 mg/day or 150 mg three times per week) and clinically significant toxicity (bone marrow suppression, uveitis and arthralgia) appears to be relatively uncommon [20-22] (see Section 10).

Rifapentine is a long-acting rifamycin that allows once-weekly supervised administration (together with moxifloxacin) during the continuation phase [7]; no outcome data are available for HIV-positive individuals on ART.

### References

1. Perriens JH, St Louis ME, Mukadi YB *et al.* Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. *N Engl J Med* 1995; **332**: 779–784.
2. el-Sadr WM, Perlman DC, Matts JP *et al.* Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Bein Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). *Clin Infect Dis* 1998; **26**: 1148–1158.
3. Kassim S, Sassan-Morokro M, Ackah A *et al.* Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. *AIDS* 1995; **9**: 1185–1191.
4. Sterling TR, Alwood K, Gachuhi R *et al.* Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. *AIDS* 1999; **13**: 1899–1904.
5. Gillespie SH, Crook AM, McHugh TD *et al.* Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. *N Engl J Med* 2014; **371**: 1577–1587.

6. Jawahar MS, Banurekha VV, Paramasivan CN *et al.* Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. *PLoS One* 2013; **8**: e67030.
7. Jindani A, Harrison TS, Nunn AJ *et al.* High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. *N Engl J Med* 2014; **371**: 1599–1608.
8. Merle CS, Fielding K, Sow OB *et al.* A four-month gatifloxacin-containing regimen for treating tuberculosis. *N Engl J Med* 2014; **371**: 1588–1598.
9. Narendran G, Menon PA, Venkatesan P *et al.* Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. *Clin Infect Dis* 2014; **59**: 1798–1804.
10. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. *Int J Tuberc Lung Dis* 1999; **3**: S231–279.
11. Grosset J. Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy. *Chest* 1981; **80**: 719–720.
12. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. *Microbiol Spectr* 2013; **2**: 1–12.
13. Wallis RS, Doherty TM, Onyebujoh P *et al.* Biomarkers for tuberculosis disease activity, cure, and relapse. *Lancet Infect Dis* 2009; **9**: 162–172.
14. NICE. *Tuberculosis. NICE guideline [NG33]*. 2016. Available at: <http://www.nice.org.uk/guidance/ng33> (accessed November 2017).
15. Thwaites GE, Nguyen DB, Nguyen HD *et al.* Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N Engl J Med* 2004; **351**: 1741–1751.
16. van Toorn R, Schaaf HS, Laubscher JA *et al.* Short intensified treatment in children with drug-susceptible tuberculous meningitis. *Pediatr Infect Dis J* 2014; **33**: 248–252.
17. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. *Cochrane Database Syst Rev* 2007; CD005159.
18. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. *Tuber Lung Dis* 1994; **75**: 341–347.
19. McGregor MM, Olliaro P, Wolmarans L *et al.* Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. *Am J Respir Crit Care Med* 1996; **154**: 1462–1467.
20. Yapa HM, Boffito M, Pozniak A. Critical review: what dose of rifabutin is recommended with antiretroviral therapy? *J Acquir Immune Defic Syndr* 2016; **72**: 138–152.
21. Rawson TM, Brima N, Almajid F *et al.* Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy. *J Acquir Immune Defic Syndr* 2015; **68**: e84–87.
22. Singh R, Marshall N, Smith CJ *et al.* No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfecting patients. *AIDS* 2013; **27**: 481–484.

## Appendix 6. Drug–drug interactions of MDR TB drugs and ART

---

### *Amikacin/kanamycin/streptomycin*

- An interaction with FTC, 3TC or TDF is unlikely as most aminoglycosides are eliminated by renal glomerular filtration rather than active transport. However, as aminoglycosides are nephrotoxic, monitor renal function.
- Since aminoglycosides are nephrotoxic, renal function should be monitored periodically as changes in the renal function may impair FTC elimination. Co-administration with nephrotoxic agents is unlikely to be of concern for TAF.

### *Capreomycin*

- Capreomycin is possibly excreted partly by tubular secretion. There is potential for exposure of capreomycin or FTC/3TC/TDF/TAF to be increased via competition for renal transporters.
- Since aminoglycosides are nephrotoxic, renal function should be monitored periodically as changes in the renal function may impair FTC elimination. Co-administration with nephrotoxic agents is unlikely to be of concern for TAF.
- Cobicistat is unlikely to inhibit OAT and OCT renal transporters at clinically relevant concentrations, therefore an interaction with capreomycin is unlikely.

### *Levofloxacin*

- Levofloxacin may cause QTc prolongation and the European SPC for ATV, LPV, EFV and RPV advise caution when co-prescribing with drugs known to induce QTc interval prolongation. There is no warning concerning DRV with RTV or COBI.
- Levofloxacin is eliminated renally, mainly by glomerular filtration and active tubular secretion. *In vitro* data indicate that levofloxacin inhibits OCT2 and could potentially increase 3TC concentrations.

### *Moxifloxacin*

- Moxifloxacin may cause QTc prolongation and the European SPC for ATV, LPV, EFV and RPV advise caution when co-prescribing with drugs known to induce QTc interval prolongation. There is no warning concerning DRV with RTV or COBI.
- Moxifloxacin is predominantly glucuronidated by UGT1A1. EFV and ETV induce UGT1A1 and therefore could potentially decrease moxifloxacin levels.

### *Para-aminosalicylic acid*

- RPV does not inhibit OCT2 in the range of clinically relevant concentrations [1].
- As para-aminosalicylic acid and FTC, 3TC, TDF are predominantly renally eliminated, including active tubular secretion, there is potential for competition for elimination via renal transport proteins, which may lead to increased concentrations of either drug.

### *Clofazimine*

- Pharmacokinetic interaction is unlikely. However, caution must be used as clofazimine with LPV/r, ATV/r, RPV, EFV may prolong the QTc interval.

### *Bedaquiline*

- Bedaquiline is metabolised by CYP3A4 and moderate or strong CYP3A4 inhibitors (such as ATV, DRV, RTV, COBI, LPV) may increase bedaquiline exposure, which could potentially increase the risk of adverse reactions.
- Bedaquiline prolongs the QTc interval. When bedaquiline is co-administered with other medicinal products that prolong the QTc interval (ATV, LPV, RPV, EFV), an additive or synergistic effect on QTc prolongation cannot be excluded. The combination of bedaquiline and moderate or strong CYP3A4

inhibitors used systemically for more than 14 consecutive days should be avoided. If co-administration is necessary, clinical monitoring, including frequent electrocardiogram assessment and monitoring of transaminases, is recommended.

- Co-administration of bedaquiline (400 mg single dose) and LPV/r (400/100 mg twice daily) to 16 HIV/TB-negative subjects increased bedaquiline AUC by 22% and had no effect on  $C_{max}$ .
- Co-administration of bedaquiline (400 mg single dose) and EFV (600 mg once daily) to 33 HIV/TB-negative subjects decreased bedaquiline AUC by 18% and had no effect on  $C_{max}$ . EFV pharmacokinetics were similar to historical data from HIV-infected subjects.
- ETR may reduce bedaquiline exposure due to induction of CYP3A4, resulting in loss of activity.
- Co-administration of bedaquiline (400 mg single dose) and NVP (200 mg twice daily for 4 weeks) in HIV-infected individuals had no clinically relevant effect on bedaquiline exposure (AUC increased by 3%,  $C_{max}$  decreased by 20%).

### Delamanid

- QTc prolongation has been observed in individuals treated with delamanid. This prolongation increases slowly over time in the first 6–10 weeks of treatment and remains stable thereafter. QTc prolongation is very closely correlated with the major delamanid metabolite DM-6705. Plasma albumin and CYP3A4 regulate the formation and metabolism of DM-6705 respectively. Treatment with delamanid should not be initiated in individuals taking medicinal products that are known to prolong the QTc interval (e.g. ATV, LPV, RPV, EFV) unless the possible benefit of delamanid is considered to outweigh the potential risks. Such individuals should receive very frequent monitoring of ECG throughout the full delamanid treatment period.
- Co-administration of delamanid with a strong inhibitor of CYP3A4 (LPV/r) was associated with a 30% higher exposure to the metabolite DM-6705, which has been associated with QTc prolongation. Therefore, if co-administration of delamanid with any strong inhibitor of CYP3A4 is considered necessary it is recommended that there is very frequent monitoring of ECGs throughout the full delamanid treatment period.
- The complete metabolic profile of delamanid has not yet been elucidated, and there is a potential for drug interactions with other co-administered medications, if significant unknown metabolites are discovered.

For latest drug interaction recommendations, and for details of the supporting evidence, and changes in drug exposure, please see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) and/or <http://hivclinic.ca/drug-information/drug-interaction-tables/>

### References

1. Moss DM, Liptrott NJ, Curley P *et al.* Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. *Antimicrob Agents Chemother* 2013; **57**: 5612–5618.

## Appendix 7. IRIS

### Definition [1]

Proposed case definition for TB- PARADOXICAL IRIS	
<b>Clinical criteria</b> <b>At least one major or two minor clinical criteria must be met. The absence of alternative explanations for clinical deterioration is also required.</b>	
<b>Major criteria</b>	(1) New or enlarging lymph nodes, cold abscesses or other focal tissue involvement (2) New or worsening radiological features of TB (includes chest radiograph, abdominal ultrasound or CT scan features) (3) New or worsening central nervous system TB (meningitis or focal neurological involvement) (4) New or worsening serositis (pleural effusion, ascites, pericardial effusion or arthritis)
<b>Minor criteria</b>	(1) New or worsening constitutional symptoms such as fever, night sweats, or weight loss (2) New or worsening respiratory symptoms such as cough, dyspnoea, or stridor (3) New or worsening abdominal pain (4) In retrospect, the resolution of clinical or radiological findings of the IRIS episode without having made a change in TB treatment
Alternative explanations for clinical deterioration to be excluded	(1) Failure of TB treatment due to drug resistance (2) Another opportunistic infection or neoplasm (it is particularly important to exclude an alternative diagnosis in individuals with smear-negative PTB and extra-pulmonary TB where the initial TB diagnosis has not been microbiologically confirmed) (3) Drug toxicity or reaction

Proposed case definition for TB- UNMASKING IRIS	
<b>Clinical criteria</b> <b>Major and one of two minor clinical criteria must be met.</b>	
<b>Major criteria</b>	Patient is not receiving treatment for tuberculosis when ART is initiated and then presents with active tuberculosis within 3 months of starting ART
<b>Minor criteria</b>	(1) Heightened intensity of clinical manifestations, particularly if there is evidence of a marked inflammatory component to the presentation.  (2) Once established on tuberculosis treatment, a clinical course that is complicated by a paradoxical reaction

### Epidemiology of IRIS

In the ART era, IRIS has been reported widely. Two studies reported respectively IRIS occurrence in 36% (12 of 33) and 32% (6 of 19) of individuals [2,3]. Another study did not find any significant difference in onset of IRIS in individuals receiving ART (3 of 28 [11%]) compared with individuals not on antiretroviral treatment (3 of 44 [7%]) [4].

According to the literature the majority of reactions occur within 60 days of initiating ART, with a median of 15 days [5]. IRIS does not appear to be associated with any particular antiretroviral regimen or drug class [6].

Most individuals with IRIS have advanced HIV infection (in one study the median baseline CD4+ count was 35 cells/mm<sup>3</sup>, and median HIV viral load >500,000 HIV-1 RNA copies/mL).

In the CAMELIA trial the risk of IRIS was increased around four fold if ART was started in the first 2 weeks compared with delaying ART until beyond week 8 of TB treatment [7].

## References

1. Meintjes G, Lawn SD, Scano F *et al.* Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis* 2008; **8**: 516–513.
2. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. *Am J Respir Crit Care Med* 1998; **158**: 157–161.
3. Navas E, Martin-Davila P, Moreno L *et al.* Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. *Arch Intern Med* 2002; **162**: 97–99.
4. Wendel KA, Alwood KS, Gachuhi R *et al.* Paradoxical worsening of tuberculosis in HIV-infected persons. *Chest* 2001; **120**: 193–197.
5. Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. *Am J Med* 1999; **106**: 371–372.
6. Michailidis C, Pozniak AL, Mandalia S *et al.* Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. *Antivir Ther* 2005; **10**: 417–422.
7. Blanc FX, Sok T, Laureillard D *et al.* Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. *XVIII International AIDS Conference*. Vienna, Austria.

## Appendix 8. When to start ART in TB/HIV infection

It is only in individuals with CD4+ cell count  $<50$  cells/mm<sup>3</sup> that trials have consistently shown clinical benefit of starting ART within 2–4 weeks of starting TB therapy as opposed to deferring ART for up to 2 months. The ACTG A5221 (STRIDE) trial compared early ( $<2$  weeks) vs. delayed (8–12 weeks) introduction of ART in individuals with CD4+ counts  $<250$  cells/mm<sup>3</sup>. The risk of AIDS and death (12.9 vs. 16.1%,  $P=0.45$ ) was not significantly lower with early ART in the overall study population, but in those with CD4+ cell counts  $<50$ /mm<sup>3</sup> (a pre-specified subgroup analysis), a lower incidence of AIDS and death was observed with early ART (15.5 vs. 26.6%,  $P=0.02$ ) [1]. The SAPIT trial compared early ( $<4$  weeks) versus delayed (8–12 weeks) ART in individuals with CD4+ cell counts  $<500$  cells/mm<sup>3</sup>. The risk of AIDS and death (6.9 vs. 7.8%,  $P=0.73$ ) was not significantly lower with early ART in this study but a lower incidence of AIDS and death was observed with early ART in those with CD4+ cell counts  $<50$  cells/mm<sup>3</sup> (8.5 vs. 26.3%,  $P=0.06$ ) [2]. The CAMELIA trial compared outcomes in individuals with HIV/TB co-infection with CD4+ cell counts  $<200$  cells/mm<sup>3</sup> who started ART at 2 vs. 8 weeks after commencing TB treatment. Early introduction of ART was associated with a 38% ( $P=0.006$ ) reduction in mortality; older age, low Karnofsky score, disseminated and multidrug-resistant TB were other predictors of death [3].

For individuals with CD4+ cell counts 50–200 cells/mm<sup>3</sup>, the clinical benefit of early ART (2–4 weeks vs. 8–12 weeks) is less clear. The CAMELIA trial showed lower mortality [3] whereas the SAPIT trial [2] and ACTG A5221 trial [1] did not. For individuals with CD4+  $>200$  cells/mm<sup>3</sup> there is no mortality benefit from starting ART sooner than 2 months after start of TB therapy. The largest of the RCTs, which included individuals with HIV/TB co-infection with CD4+ cell counts  $>220$  cells/mm<sup>3</sup>, showed that ART could be deferred until after 6 months of TB treatment without any increase in TB treatment failure or death [4]. By contrast, the SAPIT study found that sequential therapy (6 months of TB treatment followed by ART) was inferior to an integrated strategy (ART initiated during TB treatment), with significantly higher mortality in both the low ( $<200$  cells/mm<sup>3</sup>) and high (200–500 cells/mm<sup>3</sup>) CD4+ cell count stratum [5]. A trend towards improved outcomes with integrated treatment was also reported in individuals with CD4+ cell counts  $>350$  cells/mm<sup>3</sup> [6]. Similar rates of suppression of HIV replication were observed in these trials with early [1–3] vs. delayed ART [1,3,7].

### References

1. Havlir DV, Kendall MA, Ive P *et al.* Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med* 2011; **365**: 1482–1491.
2. Abdool Karim SS, Naidoo K, Grobler A *et al.* Integration of antiretroviral therapy with tuberculosis treatment. *N Engl J Med* 2011; **365**: 1492–1501.
3. Blanc FX, Sok T, Laureillard D *et al.* Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med* 2011; **365**: 1471–1481.
4. Mfinanga SG, Kirenga BJ, Chanda DM *et al.* Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. *Lancet Infect Dis* 2014; **14**: 563–571.
5. Abdool Karim SS, Naidoo K, Grobler A *et al.* Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med* 2010; **362**: 697–706.
6. Nanteza MW, Mayanja-Kizza H, Charlebois E *et al.* A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4(+) T-cell counts of  $\geq 350$  cells/ $\mu$ L. *J Infect Dis* 2011; **204**: 884–892.
7. Naidoo K, Yende-Zuma N, Padayatchi N *et al.* The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPIT trial. *Ann Intern Med* 2012; **157**: 313–324.

## Appendix 9. Glossary

3TC	Lamivudine
ABC	Abacavir
ADA	Adenosine deaminase
ADR	Acquired drug resistance
AFB	Acid-fast bacilli
AIDS	Acquired immunodeficiency syndrome
ALT	Alanine transaminase
Amx/clv	Amoxicilline/clavulanate
ART	Antiretroviral therapy
AST	Aspartate aminotransferase
ATP	Adenosine triphosphate synthase
ATV	Atazanavir
ATV/c	Atazanavir/cobicistat
ATV/r	Atazanavir/ritonavir
AUC	Area Under under the curve
AZT	Zidovudine
BAL	Bronchoalveolar lavage
BCG	Bacille-Calmette-Guérin
Bdq	Bedaquiline
BHIVA	British HIV association
CBNAAT	Cartridge-based NAAT
Cfz	Clofazimine
CM	Capreomycin
CME	Continuing medical education
CMV	Cytomegalovirus
CNS	Central nervous system
COBI	Cobicistat
COPD	Chronic obstructive pulmonary disease
CRS	Creditor reporting system
Cs	Cycloserine
CSF	Cerebrospinal fluid
C <sub>trough</sub>	Trough concentration
CYP	Cytochrome P
DDIs	Drug–drug interactions

DILI	Drug-induced liver injury
Dlm	Delamanid
DOT	Directly observed treatment
DRTB	Drug-resistant tuberculosis
DRV	Darunavir
DRV/c	Darunavir/cobicistat
DRV/r	Darunavir/ritonavir
DST	Drug-susceptibility testing
E	Ethambutol
eDOT	Electronic directly observed treatment
EFV	Efavirenz
EMA	European Medicines Agency
EPTB	Extra-pulmonary tuberculosis
ETH	Ethambutol
Eto	Ethionamide
ETR	Etravirine
EVG/c	Elvitegravir/cobicistat
FTC	Emtricitabine
GFX	Gatifloxacin
GPP	Good practice points
GRADE	Grading of Recommendations Assessment Development and Evaluation
H	Isoniazid
H <sup>H</sup>	High-dose isoniazid
HIV	Human immune deficiency virus
IGRA	Interferon gamma release assay
INH	Isoniazid
IPT	Isoniazid preventative therapy
IRD	Immune reconstitution disease
IRIS	Immune reconstitution inflammatory syndrome
ITU	Intensive treatment unit
KM	Kanamycin
LF-LAM	Lateral flow lipoarabinomannan
LTBI	Latent tb TB infection
Lzd	Linezolid
MAC	<i>Mycobacterium avium</i> complex
MDG	Millennium development goal

MDR	Multidrug-resistant
MDT	Multidisciplinary team
MRI	Magnetic resonance imaging
MTB	<i>Mycobacterium tuberculosis</i>
MVC	Maraviroc
MXF	Moxifloxacin
NAAT	Nucleic acid amplification test
NICE	National Institute for Health and Care
NNRTIs	Non-nucleoside reverse transcriptase inhibitors
NRTIs	Nucleoside reverse transcriptase inhibitors
NVP	Nevirapine
PCR	Polymerase chain reaction
PI	Protease inhibitor
PLWH	People living with HIV
POC	Point of care
Pto	Prothionamide
PZA	Pyrazinamide
QTc	Corrected QT interval
R	Rifampicin
RAL	Raltegravir
Rbt	Rifabutin
RCT	Randomised clinical trials
Rif	Rifampicin
RR	Rifampicin-resistant
RTV	Ritonavir
SAE	Serious adverse event
SHA	System of health accounts
SNP	Single nucleotide polymorphism
STD	Sexually transmitted disease
T20	Enfuvirtide
TAF	Tenofovir alafenamide
TB	Tuberculosis
TBM	Tubercular meningitis
TDF	Tenofovir disoproxil fumarate
TDM	Therapeutic drug monitoring
TNF	Tumour necrosis factor

Trd	Terizidone
TST	Tuberculin skin test
UK-CAB	UK Community Advisory Board
VOIT	Voice over internet protocol
VOT	Video-observed treatment
WHO	World Health Organization
XDR-TB	Extensively drug-resistant TB
Z	Pyrazinamide
ZN	Ziehl–Nielsen

Consultation draft